



Clinical trial results:

A phase II observer-blind, multicentre, dose-ranging study of children 6 to less than 36 months of age who are to be primed with a 2-dose series of GSK Biologicals' AS03 adjuvanted A/Indonesia/05/2005 (H5N1) vaccine.

Summary

EudraCT number	2015-003458-42
Trial protocol	PL Outside EU/EEA
Global end of trial date	13 February 2018

Results information

Result version number	v1 (current)
This version publication date	08 September 2018
First version publication date	08 September 2018

Trial information

Trial identification

Sponsor protocol code	116938
-----------------------	--------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	GlaxoSmithKline Biologicals
Sponsor organisation address	Rue de l'Institut, 89, Rixensart, Belgium, 1330
Public contact	Clinical Disclosure Advisor, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalSupportHD@gsk.com
Scientific contact	Clinical Disclosure Advisor, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalSupportHD@gsk.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMA-000160-PIP01-07
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	15 June 2018
Is this the analysis of the primary completion data?	Yes
Primary completion date	13 February 2018
Global end of trial reached?	Yes
Global end of trial date	13 February 2018
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

Primary Doses

- To assess the performance of alternative dosing regimens for primary immunization with Q-Pan H5N1 vaccine using an immunogenicity-fever index that considers:
 - immunogenicity by Hemagglutination Inhibition (HI) assay 21 days after the second priming dose.
 - fever scores after the first and second priming doses.
 - immunogenicity by Microneutralization (MN) assay 21 days after the second priming dose.
 - fever scores after the first and second priming doses.

Booster Dose

- To assess the performance of dosing regimens for booster immunization with Q-Pan H5N1 vaccine considering:
 - immune response (IR) by HI assay 7 days after a 12-month booster dose of Hemagglutinin (HA) Q-Pan H5N1 plain antigen.
 - immune response by MN assay 7 days after a 12-month booster dose of HA Q-Pan H5N1 plain antigen.

Protection of trial subjects:

All subjects were supervised/observed for 30 minutes after vaccination/product administration with appropriate medical treatment readily available. Vaccines/products were administered by qualified and trained personnel. Vaccines/products were administered only to eligible subjects that had no contraindications to any components of the vaccines/products. Subjects were followed-up for 30 days after the last vaccination/product administration.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	07 July 2016
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Taiwan: 105
Country: Number of subjects enrolled	Thailand: 80
Worldwide total number of subjects	185
EEA total number of subjects	0

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37	0

wk	
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	110
Children (2-11 years)	75
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details: -

Pre-assignment period milestones

Number of subjects started	185
----------------------------	-----

Number of subjects completed	185
------------------------------	-----

Period 1

Period 1 title	Overall Study (overall period)
----------------	--------------------------------

Is this the baseline period?	Yes
------------------------------	-----

Allocation method	Randomised - controlled
-------------------	-------------------------

Blinding used	Double blind ^[1]
---------------	-----------------------------

Roles blinded	Subject, Monitor, Data analyst, Carer, Assessor
---------------	---

Blinding implementation details:

Observer-blind study

Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

Arm title	H5N1 Formulation 1 Group
------------------	--------------------------

Arm description:

Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 1 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered intramuscularly (IM) in anterolateral thigh.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Influenza A (H5N1) Virus Monovalent Vaccine 1.9 mcg, Adjuvanted with AS03B
--	--

Investigational medicinal product code	
--	--

Other name	Split-virion Monovalent, A/Indonesia/5/2005 (H5N1)
------------	--

Pharmaceutical forms	Suspension for injection
----------------------	--------------------------

Routes of administration	Intramuscular use
--------------------------	-------------------

Dosage and administration details:

2 primary doses and 1 booster dose (unadjuvanted) were administered IM in anterolateral thigh.

Arm title	H5N1 Formulation 2 Group
------------------	--------------------------

Arm description:

Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 2 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered IM in anterolateral thigh.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Influenza A (H5N1) Virus Monovalent Vaccine 0.9 mcg, Adjuvanted with AS03C
--	--

Investigational medicinal product code	
--	--

Other name	Split-virion Monovalent, A/Indonesia/5/2005 (H5N1)
------------	--

Pharmaceutical forms	Suspension for injection
----------------------	--------------------------

Routes of administration	Intramuscular use
--------------------------	-------------------

Dosage and administration details:

2 primary doses and 1 booster dose (unadjuvanted) were administered IM in anterolateral thigh.

Arm title	H5N1 Formulation 3 Group
------------------	--------------------------

Arm description:

Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 3 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered IM in anterolateral thigh.

Arm type	Experimental
Investigational medicinal product name	Influenza A (H5N1) Virus Monovalent Vaccine 1.9 mcg, Adjuvanted with AS03C
Investigational medicinal product code	
Other name	Split-virion Monovalent, A/Indonesia/5/2005 (H5N1)
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

2 primary doses and 1 booster dose (unadjuvanted) were administered IM in anterolateral thigh.

Arm title	H5N1 Formulation 4 Group
------------------	--------------------------

Arm description:

Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 4 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered IM in anterolateral thigh.

Arm type	Experimental
Investigational medicinal product name	Influenza A (H5N1) Virus Monovalent Vaccine 3.75 mcg, Adjuvanted with AS03C
Investigational medicinal product code	
Other name	Split-virion Monovalent, A/Indonesia/5/2005 (H5N1)
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

2 primary doses and 1 booster dose (unadjuvanted) were administered IM in anterolateral thigh.

Arm title	H5N1 Formulation 5 Group
------------------	--------------------------

Arm description:

Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 5 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered IM in anterolateral thigh.

Arm type	Experimental
Investigational medicinal product name	Influenza A (H5N1) Virus Monovalent Vaccine 3.75 mcg, Adjuvanted with AS03D
Investigational medicinal product code	
Other name	Split-virion Monovalent, A/Indonesia/5/2005 (H5N1)
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

2 primary doses and 1 booster dose (unadjuvanted) were administered IM in anterolateral thigh.

Notes:

[1] - The roles blinded appear to be inconsistent with a double blind trial.

Justification: During the course of the study, the vaccine recipient, the subject's parent(s)/LAR(s) and the site and sponsor personnel involved in the clinical evaluation of the subjects are blinded while other study personnel may be aware of the treatment assignment. The laboratory in charge of the laboratory testing will be blinded to the treatment, and codes will be used to link the subject and study (without any link to the treatment attributed to the subject) to each sample.

Number of subjects in period 1	H5N1 Formulation 1 Group	H5N1 Formulation 2 Group	H5N1 Formulation 3 Group
Started	38	37	38
Completed	37	34	38
Not completed	1	3	0
Consent withdrawal	-	2	-
Migrated/moved from study area	-	-	-
Lost to follow-up	1	1	-

Number of subjects in period 1	H5N1 Formulation 4 Group	H5N1 Formulation 5 Group
Started	37	35
Completed	36	33
Not completed	1	2
Consent withdrawal	1	-
Migrated/moved from study area	-	2
Lost to follow-up	-	-

Baseline characteristics

Reporting groups

Reporting group title	H5N1 Formulation 1 Group
Reporting group description:	
Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 1 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered intramuscularly (IM) in anterolateral thigh.	
Reporting group title	H5N1 Formulation 2 Group
Reporting group description:	
Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 2 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered IM in anterolateral thigh.	
Reporting group title	H5N1 Formulation 3 Group
Reporting group description:	
Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 3 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered IM in anterolateral thigh.	
Reporting group title	H5N1 Formulation 4 Group
Reporting group description:	
Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 4 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered IM in anterolateral thigh.	
Reporting group title	H5N1 Formulation 5 Group
Reporting group description:	
Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 5 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered IM in anterolateral thigh.	

Reporting group values	H5N1 Formulation 1 Group	H5N1 Formulation 2 Group	H5N1 Formulation 3 Group
Number of subjects	38	37	38
Age categorical			
Units: Subjects			
Infants and toddlers	22	18	22
Children	16	19	16
Age continuous			
Units: months			
arithmetic mean	21.9	22.6	21.6
standard deviation	± 8.0	± 8.1	± 9.2
Gender categorical			
Units: Subjects			
Female	17	14	16
Male	21	23	22
Race/Ethnicity, Customized			
Units: Subjects			
Asian - East Asian Heritage	21	21	22
Asian - South East Asian Heritage	16	16	16
Unspecified	1	0	0

Reporting group values	H5N1 Formulation 4 Group	H5N1 Formulation 5 Group	Total
------------------------	--------------------------	--------------------------	-------

Number of subjects	37	35	185
Age categorical			
Units: Subjects			
Infants and toddlers	23	25	110
Children	14	10	75
Age continuous			
Units: months			
arithmetic mean	20.8	20.3	
standard deviation	± 8.3	± 7.8	-
Gender categorical			
Units: Subjects			
Female	23	18	88
Male	14	17	97
Race/Ethnicity, Customized			
Units: Subjects			
Asian - East Asian Heritage	21	19	104
Asian - South East Asian Heritage	16	16	80
Unspecified	0	0	1

End points

End points reporting groups

Reporting group title	H5N1 Formulation 1 Group
Reporting group description: Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 1 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered intramuscularly (IM) in anterolateral thigh.	
Reporting group title	H5N1 Formulation 2 Group
Reporting group description: Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 2 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered IM in anterolateral thigh.	
Reporting group title	H5N1 Formulation 3 Group
Reporting group description: Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 3 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered IM in anterolateral thigh.	
Reporting group title	H5N1 Formulation 4 Group
Reporting group description: Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 4 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered IM in anterolateral thigh.	
Reporting group title	H5N1 Formulation 5 Group
Reporting group description: Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 5 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered IM in anterolateral thigh.	

Primary: Humoral immune response for A/Indonesia/05/2005 (H5N1) strain in terms of vaccine-homologous Haemagglutination Inhibition (HI) antibody titers following primary vaccination

End point title	Humoral immune response for A/Indonesia/05/2005 (H5N1) strain in terms of vaccine-homologous Haemagglutination Inhibition (HI) antibody titers following primary vaccination ^[1]
End point description: The HI antibody titres were expressed in terms of immunogenicity indices for each group. Immunogenicity index (DGMT) = If the LL of the 95% CI for GMT group ratio is less than 0.25 then DGMT =0. If the LL of the 95% CI for GMT group ratio is greater than 1 then DGMT =1.	
End point type	Primary
End point timeframe: At Day 42	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	H5N1 Formulation 1 Group	H5N1 Formulation 2 Group	H5N1 Formulation 3 Group	H5N1 Formulation 4 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	36	33	37	31
Units: Immunogenicity Index				
arithmetic mean (full range (min-max))				
Immunogenicity Index	1 (0 to 1)	0.54 (0 to 1)	0.57 (0 to 1)	0.40 (0 to 1)

End point values	H5N1 Formulation 5 Group			
Subject group type	Reporting group			
Number of subjects analysed	35			
Units: Immunogenicity Index				
arithmetic mean (full range (min-max))				
Immunogenicity Index	0.34 (0 to 1)			

Statistical analyses

No statistical analyses for this end point

Primary: Humoral immune response for A/Indonesia/05/2005 (H5N1) strain in terms of vaccine-homologous Microneutralization (MN) antibody titers following primary vaccination

End point title	Humoral immune response for A/Indonesia/05/2005 (H5N1) strain in terms of vaccine-homologous Microneutralization (MN) antibody titers following primary vaccination ^[2]
-----------------	--

End point description:

The MN antibody titres were expressed in terms of immunogenicity indices for each group.
Immunogenicity index (DGMT) = If the LL of the 95% CI for GMT group ratio is less than 0.25 then DGMT =0. If the LL of the 95% CI for GMT group ratio is greater than 1 then DGMT =1.

End point type	Primary
----------------	---------

End point timeframe:

At Day 42

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	H5N1 Formulation 1 Group	H5N1 Formulation 2 Group	H5N1 Formulation 3 Group	H5N1 Formulation 4 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	36	31	37	29
Units: Immunogenicity Index				
arithmetic mean (full range (min-max))				
Immunogenicity Index	1 (0 to 1)	0.56 (0 to 1)	0.57 (0 to 1)	0.32 (0 to 1)

End point values	H5N1 Formulation 5 Group			
Subject group type	Reporting group			
Number of subjects analysed	35			
Units: Immunogenicity Index				
arithmetic mean (full range (min-max))				
Immunogenicity Index	0.33 (0 to 1)			

Statistical analyses

No statistical analyses for this end point

Primary: Evaluation of Fever index for A/Indonesia/05/2005 (H5N1) strain in terms of vaccine-homologous Haemagglutination Inhibition (HI) antibody titers following primary vaccination.

End point title	Evaluation of Fever index for A/Indonesia/05/2005 (H5N1) strain in terms of vaccine-homologous Haemagglutination Inhibition (HI) antibody titers following primary vaccination. ^[3]
-----------------	--

End point description:

Fever index was defined as the average temperature for each vaccine group. Fever index (DR) = The average temperature measurement for each vaccine group. Fever index from Days 0-2 after each dose. Any temperature < 38°C (100.4 F) was assigned a value of 0. Any temperature > 40.5°C was assigned a value of 40.5. DR correspond to 243 minus the sum of recorded temperature values for 3 days after (dose 1 and dose 2)/243.

End point type	Primary
----------------	---------

End point timeframe:

During the 3-day follow-up period (i.e. on the day of vaccination and 2 subsequent days) after Dose 1 and Dose 2.

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	H5N1 Formulation 1 Group	H5N1 Formulation 2 Group	H5N1 Formulation 3 Group	H5N1 Formulation 4 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	36	33	37	31
Units: Degrees Celsius				
arithmetic mean (full range (min-max))				
Degrees Celsius	0.84 (0 to 1)	0.91 (0 to 1)	0.95 (0 to 1)	0.93 (0 to 1)

End point values	H5N1 Formulation 5 Group			
------------------	--------------------------------	--	--	--

Subject group type	Reporting group			
Number of subjects analysed	35			
Units: Degrees Celsius				
arithmetic mean (full range (min-max))				
Degrees Celsius	0.94 (0 to 1)			

Statistical analyses

No statistical analyses for this end point

Primary: Evaluation of Fever index for A/Indonesia/05/2005 (H5N1) strain in terms of vaccine-homologous Microneutralization (MN) antibody titers following primary vaccination.

End point title	Evaluation of Fever index for A/Indonesia/05/2005 (H5N1) strain in terms of vaccine-homologous Microneutralization (MN) antibody titers following primary vaccination. ^[4]
-----------------	---

End point description:

Fever index was defined as the average temperature for each vaccine group. Fever index (DR)= The average temperature measurement for each vaccine group. Fever index from Days 0-2 after each dose Any temperature < 38°C (100.4 F) was assigned a value of 0. Any temperature > 40.5°C was assigned a value of 40.5. DR correspond to 243 minus the sum of recorded temperature values for 3 days after (dose 1 and dose 2)/243.

End point type	Primary
----------------	---------

End point timeframe:

During the 3-day follow-up period (i.e. on the day of vaccination and 2 subsequent days) after Dose 1 and Dose 2.

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	H5N1 Formulation 1 Group	H5N1 Formulation 2 Group	H5N1 Formulation 3 Group	H5N1 Formulation 4 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	36	31	37	29
Units: Degrees Celsius				
arithmetic mean (full range (min-max))				
Degrees Celsius	0.84 (0 to 1)	0.91 (0 to 1)	0.95 (0 to 1)	0.93 (0 to 1)

End point values	H5N1 Formulation 5 Group			
Subject group type	Reporting group			
Number of subjects analysed	35			
Units: Degrees Celsius				
arithmetic mean (full range (min-max))				
Degrees Celsius	0.94 (0 to 1)			

Statistical analyses

No statistical analyses for this end point

Primary: Mean Geometric Increase (MGI) for vaccine homologous and heterologous HI antibody titers against each of the four vaccine influenza strains.

End point title	Mean Geometric Increase (MGI) for vaccine homologous and heterologous HI antibody titers against each of the four vaccine influenza strains. ^[5]
-----------------	---

End point description:

MGI was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer (Day 392) to the pre-vaccination (Day 385) reciprocal HI titer for the vaccine virus. The vaccine strains assessed were Flu A/Indonesia/5/2005 H5N1 (homologous), Flu A/Vietnam/1194/2004 H5N1 (heterologous), Flu A/duck/Bangladesh/19097/2013 H5N1 (heterologous) and Flu A/gyrfalcon/Washington/41088-6/2014 H5N8 (heterologous).

End point type	Primary
----------------	---------

End point timeframe:

At Day 392 (relative to Day 385) post booster vaccination

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	H5N1 Formulation 1 Group	H5N1 Formulation 2 Group	H5N1 Formulation 3 Group	H5N1 Formulation 4 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	34	33	37	31
Units: Fold change				
geometric mean (confidence interval 95%)				
Flu A/Indonesia/5/2005 H5N1 HI	4.9 (3.8 to 6.3)	6.6 (4.9 to 9.0)	4.2 (3.4 to 5.3)	3.6 (2.9 to 4.5)
Flu A/duck/Bangladesh/19097/2013 H5N1 HI	5.2 (3.9 to 7.0)	6.0 (4.2 to 8.5)	4.0 (3.0 to 5.2)	3.4 (2.7 to 4.2)
Flu A/Vietnam/1194/2004 H5N1 HI	5.0 (3.7 to 6.8)	6.3 (4.5 to 8.7)	3.8 (3.0 to 4.8)	3.6 (2.9 to 4.5)
Flu A/gyrfalcon/Washington/41088-6/2014 H5N8 HI	4.5 (3.2 to 6.5)	4.9 (3.5 to 6.9)	3.1 (2.3 to 4.2)	2.9 (2.2 to 3.8)

End point values	H5N1 Formulation 5 Group			
Subject group type	Reporting group			
Number of subjects analysed	32			
Units: Fold change				
geometric mean (confidence interval 95%)				
Flu A/Indonesia/5/2005 H5N1 HI	3.4 (2.8 to 4.1)			

Flu A/duck/Bangladesh/19097/2013 H5N1 HI	2.7 (2.3 to 3.3)			
Flu A/Vietnam/1194/2004 H5N1 HI	2.8 (2.2 to 3.4)			
Flu A/gyrfalcon/Washington/41088-6/2014 H5N8 HI	2.4 (2.0 to 3.0)			

Statistical analyses

No statistical analyses for this end point

Primary: Mean Geometric Increase (MGI) for vaccine homologous and heterologous MN antibody titers against each of the 3 vaccine influenza strains.

End point title	Mean Geometric Increase (MGI) for vaccine homologous and heterologous MN antibody titers against each of the 3 vaccine influenza strains. ^[6]
-----------------	--

End point description:

MGI was defined as the geometric mean of the within-subject ratios of the post-vaccination (Day 392) reciprocal MN titer to the pre-vaccination (Day 385) reciprocal MN titer for the vaccine virus. The vaccine strains assessed were Flu A/Indonesia/5/2005 H5N1 (homologous), Flu A/Vietnam /1194/2004 H5N (heterologous) and Flu A/duck/Bangladesh/19097/2013 H5N1 (heterologous).

End point type	Primary
----------------	---------

End point timeframe:

At Day 392 (relative to Day 385) post booster vaccination

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	H5N1 Formulation 1 Group	H5N1 Formulation 2 Group	H5N1 Formulation 3 Group	H5N1 Formulation 4 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	34	33	37	31
Units: Fold change				
geometric mean (confidence interval 95%)				
Flu A/Indonesia/5/2005 H5N1 MN	4.3 (3.3 to 5.7)	4.8 (3.4 to 6.6)	3.2 (2.3 to 4.3)	2.8 (2.0 to 3.8)
Flu A/Vietnam/1194/2004 H5N1 MN	2.9 (2.2 to 3.8)	2.9 (2.1 to 4.1)	2.9 (2.2 to 3.8)	2.6 (2.1 to 3.3)
Flu A/duck/Bangladesh/19097/2013 H5N1 MN	2.6 (1.9 to 3.5)	3.0 (2.3 to 4.1)	2.6 (2.0 to 3.2)	2.1 (1.6 to 2.8)

End point values	H5N1 Formulation 5 Group			
Subject group type	Reporting group			
Number of subjects analysed	32			
Units: Fold change				
geometric mean (confidence interval 95%)				
Flu A/Indonesia/5/2005 H5N1 MN	2.5 (2.0 to 3.0)			
Flu A/Vietnam/1194/2004 H5N1 MN	2.4 (1.9 to 3.1)			

Flu A/duck/Bangladesh/19097/2013 H5N1 MN	2.8 (2.2 to 3.5)			
---	------------------	--	--	--

Statistical analyses

No statistical analyses for this end point

Secondary: Number of seroconverted subjects for HI antibodies against each of the 4 vaccine influenza strains.

End point title	Number of seroconverted subjects for HI antibodies against each of the 4 vaccine influenza strains.
End point description: Seroconversion rate (SCR) was defined as the proportion of subjects who have either a pre-vaccination reciprocal HI titer less than (<) 10 and a post-vaccination reciprocal titer greater than or equal to (≥) 40, or a pre-vaccination reciprocal HI titer ≥ 10 and at least a 4-fold increase in post vaccination reciprocal titer against the vaccine virus. The vaccine strains assessed were Flu A/Indonesia/5/2005 H5N1 (homologous), Flu A/Vietnam/1194/2004 H5N1 (heterologous), Flu A/duck/Bangladesh/19097/2013 H5N1 (heterologous) and Flu A/gyrfalcon/Washington/41088-6/2014 H5N8 (heterologous).	
End point type	Secondary
End point timeframe: At Days 42, 385 and 392	

End point values	H5N1 Formulation 1 Group	H5N1 Formulation 2 Group	H5N1 Formulation 3 Group	H5N1 Formulation 4 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	36	33	37	31
Units: Participants				
Flu A/Indonesia/5/2005 H5N1 HI, Day 42	36	33	37	31
Flu A/Indonesia/5/2005 H5N1 HI, Day 385	33	26	28	28
Flu A/Indonesia/5/2005 H5N1 HI, Day 392	34	33	37	31
Flu A/duck/Bangladesh/19097/2013 H5N1 HI, Day 42	30	22	33	23
Flu A/duck/Bangladesh/19097/2013 H5N1 HI, Day 385	7	6	7	5
Flu A/duck/Bangladesh/19097/2013 H5N1 HI, Day 392	27	29	26	21
Flu A/Vietnam/1194/2004 H5N1 HI, Day 42	30	22	29	21
Flu A/Vietnam/1194/2004 H5N1 HI, Day 385	12	8	9	5
Flu A/Vietnam/1194/2004 H5N1 HI, Day 392	29	29	28	22
Flu A/gyrfalcon/WA/41088-6/2014 H5N8 HI, Day 42	17	9	10	5
Flu A/gyrfalcon/WA/41088-6/2014 H5N8 HI, Day 385	1	0	1	0

Flu A/gyrfalcon/WA/41088-6/2014 H5N8 HI, Day 392	18	15	16	9
---	----	----	----	---

End point values	H5N1 Formulation 5 Group			
Subject group type	Reporting group			
Number of subjects analysed	35			
Units: Participants				
Flu A/Indonesia/5/2005 H5N1 HI, Day 42	35			
Flu A/Indonesia/5/2005 H5N1 HI, Day 385	21			
Flu A/Indonesia/5/2005 H5N1 HI, Day 392	32			
Flu A/duck/Bangladesh/19097/2013 H5N1 HI, Day 42	25			
Flu A/duck/Bangladesh/19097/2013 H5N1 HI, Day 385	6			
Flu A/duck/Bangladesh/19097/2013 H5N1 HI, Day 392	18			
Flu A/Vietnam/1194/2004 H5N1 HI, Day 42	24			
Flu A/Vietnam/1194/2004 H5N1 HI, Day 385	6			
Flu A/Vietnam/1194/2004 H5N1 HI, Day 392	20			
Flu A/gyrfalcon/WA/41088-6/2014 H5N8 HI, Day 42	8			
Flu A/gyrfalcon/WA/41088-6/2014 H5N8 HI, Day 385	0			
Flu A/gyrfalcon/WA/41088-6/2014 H5N8 HI, Day 392	6			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects who were seroprotected for HI antibodies against each of the 4 vaccine influenza strains.

End point title	Number of subjects who were seroprotected for HI antibodies against each of the 4 vaccine influenza strains.
-----------------	--

End point description:

Seroprotection rate (SPR) was defined as the proportion of subjects with H5N1 reciprocal HI titers ≥ 40 against the tested vaccine virus. The vaccine strains assessed were Flu A/Indonesia/5/2005 H5N1 (homologous), Flu A/Vietnam/1194/2004 H5N1 (heterologous), Flu A/duck/Bangladesh/19097/2013 H5N1 (heterologous) and Flu A/gyrfalcon/Washington/41088-6/2014 H5N8 (heterologous).

End point type	Secondary
----------------	-----------

End point timeframe:

At Days 0, 42, 385, 392

End point values	H5N1 Formulation 1 Group	H5N1 Formulation 2 Group	H5N1 Formulation 3 Group	H5N1 Formulation 4 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	36	33	37	31
Units: Participants				
Flu A/Indonesia/5/2005 H5N1 HI, Day 0	0	0	0	0
Flu A/Indonesia/5/2005 H5N1 HI, Day 42	36	33	37	31
Flu A/Indonesia/5/2005 H5N1 HI, Day 385	33	26	28	28
Flu A/Indonesia/5/2005 H5N1 HI, Day 392	34	33	37	31
Flu A/duck/Bangladesh/19097/2013 H5N1 HI, Day 0	0	0	0	0
Flu A/duck/Bangladesh/19097/2013 H5N1 HI, Day 42	32	25	35	28
Flu A/duck/Bangladesh/19097/2013 H5N1 HI, Day 385	9	8	8	7
Flu A/duck/Bangladesh/19097/2013 H5N1 HI, Day 392	30	32	27	27
Flu A/Vietnam/1194/2004 H5N1 HI, Day 0	0	0	0	0
Flu A/Vietnam/1194/2004 H5N1 HI, Day 42	32	25	31	26
Flu A/Vietnam/1194/2004 H5N1 HI, Day 385	15	10	10	7
Flu A/Vietnam/1194/2004 H5N1 HI, Day 392	32	32	29	28
Flu A/gyrfalcon/WA/41088-6/2014 H5N8 HI, Day 0	0	0	0	0
Flu A/gyrfalcon/WA/41088-6/2014 H5N8 HI, Day 42	19	10	11	7
Flu A/gyrfalcon/WA/41088-6/2014 H5N8 HI, Day 385	1	1	1	0
Flu A/gyrfalcon/WA/41088-6/2014 H5N8 HI, Day 392	20	18	16	10

End point values	H5N1 Formulation 5 Group			
Subject group type	Reporting group			
Number of subjects analysed	35			
Units: Participants				
Flu A/Indonesia/5/2005 H5N1 HI, Day 0	0			
Flu A/Indonesia/5/2005 H5N1 HI, Day 42	35			
Flu A/Indonesia/5/2005 H5N1 HI, Day 385	23			
Flu A/Indonesia/5/2005 H5N1 HI, Day 392	32			
Flu A/duck/Bangladesh/19097/2013 H5N1 HI, Day 0	2			

Flu A/duck/Bangladesh/19097/2013 H5N1 HI, Day 42	31			
Flu A/duck/Bangladesh/19097/2013 H5N1 HI, Day 385	6			
Flu A/duck/Bangladesh/19097/2013 H5N1 HI, Day 392	22			
Flu A/Vietnam/1194/2004 H5N1 HI, Day 0	2			
Flu A/Vietnam/1194/2004 H5N1 HI, Day 42	29			
Flu A/Vietnam/1194/2004 H5N1 HI, Day 385	8			
Flu A/Vietnam/1194/2004 H5N1 HI, Day 392	24			
Flu A/gyrfalcon/WA/41088-6/2014 H5N8 HI, Day 0	0			
Flu A/gyrfalcon/WA/41088-6/2014 H5N8 HI, Day 42	9			
Flu A/gyrfalcon/WA/41088-6/2014 H5N8 HI, Day 385	1			
Flu A/gyrfalcon/WA/41088-6/2014 H5N8 HI, Day 392	8			

Statistical analyses

No statistical analyses for this end point

Secondary: Geometric mean titers (GMTs) for humoral immune response in terms of HI antibodies against vaccine-homologous/heterologous antigens

End point title	Geometric mean titers (GMTs) for humoral immune response in terms of HI antibodies against vaccine-homologous/heterologous antigens
-----------------	---

End point description:

GMTs were defined as the geometric mean antibody titres calculated on all subjects post the primary immunization (at Day 0, 42, 385) and 7 days post booster dose (at Day 392). The aggregate variables were calculated for each group. The vaccine strains assessed were Flu A/Indonesia/5/2005 H5N1 (homologous), Flu A/Vietnam/1194/2004 H5N1 (heterologous), Flu A/duck/Bangladesh/19097/2013 H5N1 (heterologous) and Flu A/gyrfalcon/Washington/41088-6/2014 H5N8 (heterologous).

End point type	Secondary
----------------	-----------

End point timeframe:

At Days 0, 42 and 385 (post the primary immunization), at Day 392 (7 days post booster dose)

End point values	H5N1 Formulation 1 Group	H5N1 Formulation 2 Group	H5N1 Formulation 3 Group	H5N1 Formulation 4 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	36	33	37	31
Units: Titers				
geometric mean (confidence interval 95%)				
Flu A/Indonesia/5/2005 H5N1 HI, Day 0	5.1 (4.9 to 5.3)	5.1 (4.9 to 5.3)	5.1 (4.9 to 5.4)	5.0 (5.0 to 5.0)
Flu A/Indonesia/5/2005 H5N1 HI, Day 42	1118.6 (884.4 to 1414.9)	858.8 (659.2 to 1118.8)	913.6 (672.6 to 1241.1)	640.0 (488.3 to 839.0)

Flu A/Indonesia/5/2005 H5N1 HI, Day 385	98.1 (76.7 to 125.4)	61.5 (47.1 to 80.3)	72.1 (51.6 to 100.7)	79.1 (59.2 to 105.6)
Flu A/Indonesia/5/2005 H5N1 HI, Day 392	476.2 (348.4 to 650.9)	407.6 (315.0 to 527.4)	305.4 (227.1 to 410.6)	286.2 (216.0 to 379.1)
Flu A/duck/Bangladesh/19097/2013 H5N1 HI, Day 0	5.3 (5.0 to 5.7)	5.4 (4.8 to 5.9)	5.3 (5.0 to 5.7)	5.0 (5.0 to 5.0)
Flu A/duck/Bangladesh/19097/2013 H5N1 HI, Day 42	167.1 (128.4 to 217.3)	135.3 (97.6 to 187.5)	109.9 (81.2 to 148.7)	91.5 (70.2 to 119.1)
Flu A/duck/Bangladesh/19097/2013 H5N1 HI, Day 385	23.4 (18.8 to 29.2)	20.8 (16.3 to 26.6)	17.8 (13.2 to 24.1)	20.9 (16.1 to 26.9)
Flu A/duck/Bangladesh/19097/2013 H5N1 HI, Day 392	125.6 (89.4 to 176.5)	126.1 (95.2 to 167.0)	77.6 (54.5 to 110.4)	70.7 (52.7 to 95.0)
Flu A/Vietnam/1194/2004 H5N1 HI, Day 0	5.3 (5.0 to 5.7)	5.0 (5.0 to 5.0)	5.1 (4.9 to 5.5)	5.1 (4.9 to 5.4)
Flu A/Vietnam/1194/2004 H5N1 HI, Day 42	128.9 (103.1 to 161.2)	104.7 (79.0 to 138.6)	88.9 (63.2 to 125.0)	77.2 (59.7 to 99.9)
Flu A/Vietnam/1194/2004 H5N1 HI, Day 385	26.0 (20.0 to 33.8)	21.5 (16.8 to 27.5)	18.4 (13.2 to 25.7)	21.3 (16.3 to 27.9)
Flu A/Vietnam/1194/2004 H5N1 HI, Day 392	133.9 (95.5 to 187.7)	137.5 (107.3 to 176.1)	76.2 (53.9 to 107.7)	76.5 (56.8 to 103.1)
Flu A/gyrfalcon/WA/41088-6/2014 H5N8 HI, Day 0	5.3 (4.9 to 5.7)	5.0 (5.0 to 5.0)	5.1 (4.9 to 5.3)	5.2 (4.8 to 5.7)
Flu A/gyrfalcon/WA/41088-6/2014 H5N8 HI, Day 42	35.8 (27.9 to 46.0)	27.8 (21.1 to 36.7)	22.8 (17.2 to 30.3)	21.6 (16.7 to 27.8)
Flu A/gyrfalcon/WA/41088-6/2014 H5N8 HI, Day 385	9.2 (7.6 to 11.2)	8.0 (6.4 to 9.9)	7.4 (6.0 to 9.0)	7.7 (6.6 to 9.1)
Flu A/gyrfalcon/WA/41088-6/2014 H5N8 HI, Day 392	42.6 (29.8 to 60.8)	37.0 (27.1 to 50.6)	24.0 (17.1 to 33.6)	22.6 (16.7 to 30.5)

End point values	H5N1 Formulation 5 Group			
Subject group type	Reporting group			
Number of subjects analysed	35			
Units: Titers				
geometric mean (confidence interval 95%)				
Flu A/Indonesia/5/2005 H5N1 HI, Day 0	5.6 (4.9 to 6.5)			
Flu A/Indonesia/5/2005 H5N1 HI, Day 42	568.4 (442.7 to 729.8)			
Flu A/Indonesia/5/2005 H5N1 HI, Day 385	59.6 (45.0 to 79.0)			
Flu A/Indonesia/5/2005 H5N1 HI, Day 392	201.0 (156.1 to 258.7)			
Flu A/duck/Bangladesh/19097/2013 H5N1 HI, Day 0	6.1 (4.9 to 7.6)			
Flu A/duck/Bangladesh/19097/2013 H5N1 HI, Day 42	78.5 (58.5 to 105.3)			
Flu A/duck/Bangladesh/19097/2013 H5N1 HI, Day 385	19.5 (14.2 to 26.8)			
Flu A/duck/Bangladesh/19097/2013 H5N1 HI, Day 392	53.5 (38.6 to 74.2)			
Flu A/Vietnam/1194/2004 H5N1 HI, Day 0	5.8 (4.7 to 7.2)			
Flu A/Vietnam/1194/2004 H5N1 HI, Day 42	69.0 (51.7 to 92.0)			
Flu A/Vietnam/1194/2004 H5N1 HI, Day 385	20.6 (14.8 to 28.7)			

Flu A/Vietnam/1194/2004 H5N1 HI, Day 392	57.8 (41.5 to 80.4)			
Flu A/gyrfalcon/WA/41088-6/2014 H5N8 HI, Day 0	5.3 (4.9 to 5.8)			
Flu A/gyrfalcon/WA/41088-6/2014 H5N8 HI, Day 42	19.9 (15.4 to 25.8)			
Flu A/gyrfalcon/WA/41088-6/2014 H5N8 HI, Day 385	7.2 (5.8 to 8.8)			
Flu A/gyrfalcon/WA/41088-6/2014 H5N8 HI, Day 392	17.9 (13.4 to 23.9)			

Statistical analyses

No statistical analyses for this end point

Secondary: Mean geometric increase (MGI) for haemagglutination inhibition (HI) antibody titer against each of the 4 vaccine influenza strains

End point title	Mean geometric increase (MGI) for haemagglutination inhibition (HI) antibody titer against each of the 4 vaccine influenza strains
-----------------	--

End point description:

MGI was defined as the geometric mean of the within-subject ratios of the post-vaccination (Day 42) reciprocal HI titer to the pre-vaccination (Day 0) reciprocal HI titer for the vaccine virus. The vaccine strains assessed were Flu A/Indonesia/5/2005 H5N1 (homologous), Flu A/Vietnam/1194/2004 H5N1 (heterologous), Flu A/duck/Bangladesh/19097/2013 H5N1 (heterologous) and Flu A/gyrfalcon/Washington/41088-6/2014 H5N8 (heterologous).

End point type	Secondary
----------------	-----------

End point timeframe:

At Day 42 (relative to Day 0), at Day 385 (relative to Day 0) and at Day 392 (relative to Day 0)

End point values	H5N1 Formulation 1 Group	H5N1 Formulation 2 Group	H5N1 Formulation 3 Group	H5N1 Formulation 4 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	36	33	37	31
Units: Fold change				
geometric mean (confidence interval 95%)				
Flu A/Indonesia/5/2005 H5N1 HI, Day 42	219.5 (172.6 to 279.0)	168.2 (127.4 to 222.0)	177.7 (131.5 to 240.1)	128.0 (97.7 to 167.8)
Flu A/Indonesia/5/2005 H5N1 HI, Day 385	19.2 (14.8 to 24.9)	12.0 (9.2 to 15.8)	14.0 (10.0 to 19.7)	15.8 (11.8 to 21.1)
Flu A/Indonesia/5/2005 H5N1 HI, Day 392	93.3 (67.9 to 128.3)	79.8 (61.5 to 103.5)	59.4 (44.5 to 79.4)	57.2 (43.2 to 75.8)
Flu A/duck/Bangladesh/19097/2013 H5N1 HI, Day 42	31.3 (23.5 to 41.6)	22.9 (17.2 to 30.6)	20.4 (14.9 to 28.1)	18.9 (14.0 to 25.5)
Flu A/duck/Bangladesh/19097/2013 H5N1 HI, Day 385	4.2 (3.3 to 5.3)	3.6 (2.9 to 4.6)	3.3 (2.4 to 4.5)	3.9 (2.9 to 5.3)
Flu A/duck/Bangladesh/19097/2013 H5N1 HI, Day 392	23.4 (16.2 to 33.9)	22.9 (17.1 to 30.7)	14.5 (10.1 to 20.7)	13.9 (9.8 to 19.8)
Flu A/Vietnam/1194/2004 H5N1 HI, Day 42	24.3 (19.0 to 31.0)	20.1 (15.2 to 26.7)	16.7 (11.7 to 23.8)	15.1 (11.1 to 20.6)

Flu A/Vietnam/1194/2004 H5N1 HI, Day 385	4.7 (3.5 to 6.2)	4.1 (3.1 to 5.3)	3.5 (2.5 to 5.0)	3.9 (2.8 to 5.4)
Flu A/Vietnam/1194/2004 H5N1 HI, Day 392	25.1 (17.3 to 36.4)	27.1 (20.9 to 35.0)	14.5 (10.2 to 20.5)	14.5 (10.0 to 21.1)
Flu A/gyrfalcon/WA/41088-6/2014 H5N8 HI, Day 42	6.7 (5.0 to 9.0)	5.5 (4.0 to 7.4)	4.3 (3.2 to 5.8)	4.1 (3.0 to 5.6)
Flu A/gyrfalcon/WA/41088-6/2014 H5N8 HI, Day 385	1.7 (1.4 to 2.1)	1.5 (1.2 to 1.8)	1.4 (1.2 to 1.8)	1.5 (1.2 to 1.8)
Flu A/gyrfalcon/WA/41088-6/2014 H5N8 HI, Day 392	8.1 (5.5 to 12.0)	7.1 (5.1 to 9.9)	4.7 (3.3 to 6.7)	4.2 (3.0 to 6.0)

End point values	H5N1 Formulation 5 Group			
Subject group type	Reporting group			
Number of subjects analysed	35			
Units: Fold change				
geometric mean (confidence interval 95%)				
Flu A/Indonesia/5/2005 H5N1 HI, Day 42	101.0 (74.8 to 136.4)			
Flu A/Indonesia/5/2005 H5N1 HI, Day 385	10.5 (7.6 to 14.5)			
Flu A/Indonesia/5/2005 H5N1 HI, Day 392	35.3 (25.9 to 48.1)			
Flu A/duck/Bangladesh/19097/2013 H5N1 HI, Day 42	12.6 (9.0 to 17.6)			
Flu A/duck/Bangladesh/19097/2013 H5N1 HI, Day 385	3.3 (2.3 to 4.7)			
Flu A/duck/Bangladesh/19097/2013 H5N1 HI, Day 392	9.1 (6.0 to 13.7)			
Flu A/Vietnam/1194/2004 H5N1 HI, Day 42	11.4 (8.4 to 15.6)			
Flu A/Vietnam/1194/2004 H5N1 HI, Day 385	3.6 (2.6 to 5.2)			
Flu A/Vietnam/1194/2004 H5N1 HI, Day 392	10.1 (6.7 to 15.2)			
Flu A/gyrfalcon/WA/41088-6/2014 H5N8 HI, Day 42	3.5 (2.7 to 4.6)			
Flu A/gyrfalcon/WA/41088-6/2014 H5N8 HI, Day 385	1.3 (1.1 to 1.6)			
Flu A/gyrfalcon/WA/41088-6/2014 H5N8 HI, Day 392	3.2 (2.3 to 4.3)			

Statistical analyses

No statistical analyses for this end point

Secondary: Mean geometric increase (MGI) for MN antibodies against the 3 vaccine influenza strains.

End point title	Mean geometric increase (MGI) for MN antibodies against the 3 vaccine influenza strains.
-----------------	--

End point description:

MGI was defined as the geometric mean of the within-subject ratios of the post-vaccination (Day 385)

reciprocal MN titer to the pre-vaccination (Day 0) reciprocal MN titer for the vaccine virus. The vaccine strains assessed were Flu A/Indonesia/5/2005 H5N1 (homologous), Flu A/Vietnam /1194/2004 H5N (heterologous) and Flu A/duck/Bangladesh/19097/2013 H5N1 (heterologous).

End point type	Secondary
End point timeframe:	
At Day 385 (relative to Day 0)	

End point values	H5N1 Formulation 1 Group	H5N1 Formulation 2 Group	H5N1 Formulation 3 Group	H5N1 Formulation 4 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	34	32	37	30
Units: Fold change				
geometric mean (confidence interval 95%)				
Flu A/Indonesia/5/2005 H5N1 MN	17.5 (13.7 to 22.4)	14.8 (12.6 to 17.5)	15.3 (12.5 to 18.6)	17.8 (14.3 to 22.1)
Flu A/Vietnam/1194/2004 H5N1 MN	7.6 (5.5 to 10.3)	5.8 (4.2 to 8.1)	5.4 (4.0 to 7.4)	7.5 (5.8 to 9.8)
Flu A/duck/Bangladesh/19097/2013 H5N1 MN	7.0 (5.2 to 9.4)	5.5 (4.1 to 7.3)	5.3 (3.8 to 7.3)	6.9 (5.0 to 9.4)

End point values	H5N1 Formulation 5 Group			
Subject group type	Reporting group			
Number of subjects analysed	32			
Units: Fold change				
geometric mean (confidence interval 95%)				
Flu A/Indonesia/5/2005 H5N1 MN	14.2 (11.8 to 17.1)			
Flu A/Vietnam/1194/2004 H5N1 MN	6.1 (4.5 to 8.3)			
Flu A/duck/Bangladesh/19097/2013 H5N1 MN	4.2 (3.1 to 5.8)			

Statistical analyses

No statistical analyses for this end point

Secondary: Humoral immune response for A/Indonesia/05/2005 (H5N1) strain in terms of MN antibodies against vaccine-homologous/heterologous antigens

End point title	Humoral immune response for A/Indonesia/05/2005 (H5N1) strain in terms of MN antibodies against vaccine-homologous/heterologous antigens
-----------------	--

End point description:

MN antibody titers were expressed as Geometric Mean Titers (GMTs). The cut-off of the assay was the seropositivity cut-off of $\geq 1:28$. The vaccine strains assessed were Flu A/Indonesia/5/2005 H5N1 (homologous), Flu A/Vietnam /1194/2004 H5N (heterologous) and Flu A/duck/Bangladesh/19097/2013

H5N1 (heterologous).

End point type	Secondary
End point timeframe:	
At Days 0, 42, 385 and Day 392	

End point values	H5N1 Formulation 1 Group	H5N1 Formulation 2 Group	H5N1 Formulation 3 Group	H5N1 Formulation 4 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	36	33	37	31
Units: Titers				
geometric mean (confidence interval 95%)				
Flu A/Indonesia/5/2005 H5N1 MN, Day 0	14.3 (13.7 to 14.8)	14.0 (14.0 to 14.0)	14.0 (14.0 to 14.0)	14.0 (14.0 to 14.0)
Flu A/Indonesia/5/2005 H5N1 MN, Day 42	1498.5 (1181.7 to 1900.1)	1214.3 (921.3 to 1600.6)	1211.6 (881.3 to 1665.9)	707.1 (533.1 to 937.9)
Flu A/Indonesia/5/2005 H5N1 MN, Day 385	250.3 (197.1 to 318.0)	203.6 (172.8 to 239.8)	213.8 (175.2 to 260.9)	247.2 (201.4 to 303.5)
Flu A/Indonesia/5/2005 H5N1 MN, Day 392	1085.0 (767.5 to 1533.9)	969.1 (710.1 to 1322.6)	674.2 (492.3 to 923.3)	681.0 (496.3 to 934.4)
Flu A/Vietnam/1194/2004 H5N1 MN, Day 0	14.6 (13.8 to 15.4)	14.6 (13.7 to 15.5)	14.8 (13.6 to 16.1)	14.0 (14.0 to 14.0)
Flu A/Vietnam/1194/2004 H5N1 MN, Day 42	217.6 (187.7 to 252.2)	195.2 (156.7 to 243.1)	177.3 (147.8 to 212.7)	176.9 (139.0 to 225.2)
Flu A/Vietnam/1194/2004 H5N1 MN, Day 385	113.0 (85.3 to 149.9)	88.0 (64.0 to 121.0)	80.7 (58.7 to 111.1)	103.6 (80.5 to 133.2)
Flu A/Vietnam/1194/2004 H5N1 MN, Day 392	320.0 (259.8 to 394.1)	256.6 (212.5 to 309.9)	239.2 (202.5 to 282.7)	270.4 (237.2 to 308.3)
Flu A/duck/Bangladesh/19097/2013 H5N1 MN, Day 0	14.6 (13.8 to 15.4)	14.3 (13.7 to 15.0)	14.5 (13.5 to 15.7)	14.6 (13.7 to 15.6)
Flu A/duck/Bangladesh/19097/2013 H5N1 MN, Day 42	179.4 (146.5 to 219.7)	161.6 (129.4 to 201.9)	147.1 (116.6 to 185.7)	161.8 (129.1 to 202.8)
Flu A/duck/Bangladesh/19097/2013 H5N1 MN, Day 385	102.0 (76.6 to 135.9)	79.2 (59.3 to 105.8)	76.3 (55.7 to 104.7)	100.7 (74.2 to 136.6)
Flu A/duck/Bangladesh/19097/2013 H5N1 MN, Day 392	262.5 (212.2 to 324.7)	240.9 (197.7 to 293.6)	194.8 (157.7 to 240.7)	202.2 (167.8 to 243.7)

End point values	H5N1 Formulation 5 Group			
Subject group type	Reporting group			
Number of subjects analysed	35			
Units: Titers				
geometric mean (confidence interval 95%)				
Flu A/Indonesia/5/2005 H5N1 MN, Day 0	14.0 (14.0 to 14.0)			
Flu A/Indonesia/5/2005 H5N1 MN, Day 42	727.4 (545.9 to 969.2)			
Flu A/Indonesia/5/2005 H5N1 MN, Day 385	198.5 (165.1 to 238.7)			

Flu A/Indonesia/5/2005 H5N1 MN, Day 392	489.6 (381.7 to 628.0)			
Flu A/Vietnam/1194/2004 H5N1 MN, Day 0	15.2 (13.5 to 17.0)			
Flu A/Vietnam/1194/2004 H5N1 MN, Day 42	149.3 (117.6 to 189.6)			
Flu A/Vietnam/1194/2004 H5N1 MN, Day 385	89.0 (67.2 to 118.0)			
Flu A/Vietnam/1194/2004 H5N1 MN, Day 392	216.5 (179.0 to 261.8)			
Flu A/duck/Bangladesh/19097/2013 H5N1 MN, Day 0	15.2 (13.8 to 16.7)			
Flu A/duck/Bangladesh/19097/2013 H5N1 MN, Day 42	140.6 (111.8 to 176.8)			
Flu A/duck/Bangladesh/19097/2013 H5N1 MN, Day 385	63.0 (47.0 to 84.4)			
Flu A/duck/Bangladesh/19097/2013 H5N1 MN, Day 392	174.5 (140.5 to 216.8)			

Statistical analyses

No statistical analyses for this end point

Secondary: Vaccine response rate (VRR) for homologous and heterologous MN antibodies against each of the 3 vaccine influenza strains.

End point title	Vaccine response rate (VRR) for homologous and heterologous MN antibodies against each of the 3 vaccine influenza strains.
-----------------	--

End point description:

VRR for MN was defined as the incidence rate of subjects with at least a 4-fold increase in post vaccination reciprocal titer relative to pre vaccination titers. The vaccine strains assessed were Flu A/Indonesia/5/2005 H5N1 (homologous), Flu A/Vietnam /1194/2004 H5N (heterologous) and Flu A/duck/Bangladesh/19097/2013 H5N1 (heterologous).

End point type	Secondary
----------------	-----------

End point timeframe:

At Day 42, Day 385 (relative to Day 0), Day 392 (relative to Day 0) and D 392 (relative to Day 385)

End point values	H5N1 Formulation 1 Group	H5N1 Formulation 2 Group	H5N1 Formulation 3 Group	H5N1 Formulation 4 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	36	33	37	31
Units: Participants				
Flu A/Indonesia/5/2005 H5N1 MN, Day 42	36	31	37	29
Flu A/Indonesia/5/2005 H5N1 MN, Day 385	34	32	37	29
Flu A/Indonesia/5/2005 H5N1 MN, Day 392	34	32	37	29
Flu A/Indonesia/5/2005 H5N1 MN, D 392	21	24	14	15
Flu A/Vietnam/1194/2004 H5N1 MN, Day 42	34	31	36	29

Flu A/Vietnam/1194/2004 H5N1 MN, Day 385	27	27	27	28
Flu A/Vietnam/1194/2004 H5N1 MN, Day 392	31	31	37	30
Flu A/Vietnam/1194/2004 H5N1 MN, D 392	10	10	10	7
Flu A/duck/Bangladesh/19097/2013 H5N1 MN, Day 42	34	31	35	31
Flu A/duck/Bangladesh/19097/2013 H5N1 MN, Day 385	28	27	29	25
Flu A/duck/Bangladesh/19097/2013 H5N1 MN, Day 392	33	32	36	31
Flu A/duck/Bangladesh/19097/2013 H5N1 MN, D 392	9	10	8	6

End point values	H5N1 Formulation 5 Group			
Subject group type	Reporting group			
Number of subjects analysed	35			
Units: Participants				
Flu A/Indonesia/5/2005 H5N1 MN, Day 42	35			
Flu A/Indonesia/5/2005 H5N1 MN, Day 385	32			
Flu A/Indonesia/5/2005 H5N1 MN, Day 392	32			
Flu A/Indonesia/5/2005 H5N1 MN, D 392	13			
Flu A/Vietnam/1194/2004 H5N1 MN, Day 42	32			
Flu A/Vietnam/1194/2004 H5N1 MN, Day 385	25			
Flu A/Vietnam/1194/2004 H5N1 MN, Day 392	30			
Flu A/Vietnam/1194/2004 H5N1 MN, D 392	6			
Flu A/duck/Bangladesh/19097/2013 H5N1 MN, Day 42	32			
Flu A/duck/Bangladesh/19097/2013 H5N1 MN, Day 385	23			
Flu A/duck/Bangladesh/19097/2013 H5N1 MN, Day 392	30			
Flu A/duck/Bangladesh/19097/2013 H5N1 MN, D 392	9			

Statistical analyses

No statistical analyses for this end point

Secondary: Cell mediated Immunity (CMI) in terms of T-cell markers related to Flu A/Indonesia/05/2005 antigen.

End point title	Cell mediated Immunity (CMI) in terms of T-cell markers related to Flu A/Indonesia/05/2005 antigen.
-----------------	---

End point description:

Antigen-specific CD4+/CD8+ T Cells identified as CD4/CD8+ were analysed for T cells expressing two or more of the following immune markers: CD40 Ligand, Interleukin (IL)-2, Tumor Necrosis Factor alpha (TNF-a), Interferon-gamma (IFN-g). The frequency was presented as number of cytokine-producing CD4+/CD8+ cells per million CD4+/CD8+ cells respectively. All doubles = T cell expressing at least 2 cytokines.

End point type	Secondary
End point timeframe:	
At Days 0, 42, 385 and 392	

End point values	H5N1 Formulation 1 Group	H5N1 Formulation 2 Group	H5N1 Formulation 3 Group	H5N1 Formulation 4 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	19	19	18
Units: cells/million T cells				
median (inter-quartile range (Q1-Q3))				
CD4 dble_All (Polypositives), Day 0	55.5 (1.0 to 227.0)	42.0 (3.0 to 185.0)	43.0 (1.0 to 90.0)	89.5 (26.0 to 217.0)
CD4 dble_All (Polypositives), Day 42	2711.0 (1669.0 to 5165.0)	1629.0 (707.0 to 4301.0)	960.0 (432.0 to 1379.0)	1337.5 (748.0 to 2793.0)
CD4 dble_All (Polypositives), Day 385	1530.0 (632.5 to 2293.5)	1255.0 (560.0 to 2096.0)	1413.0 (469.0 to 1834.0)	954.0 (495.0 to 1199.0)
CD4 dble_All (Polypositives), Day 392	1417.0 (759.5 to 3955.5)	1129.0 (582.0 to 3221.0)	731.0 (448.0 to 1461.0)	722.5 (260.0 to 907.0)
CD4 dble_CD40L, Day 0	23.0 (1.0 to 56.0)	19.0 (1.0 to 52.0)	5.0 (1.0 to 60.0)	36.0 (1.0 to 85.0)
CD4 dble_CD40L, Day 42	1671.0 (635.0 to 3256.0)	1341.0 (378.0 to 2696.0)	514.0 (229.0 to 1200.0)	516.0 (307.5 to 2031.0)
CD4 dble_CD40L, Day 385	1074.0 (562.5 to 2637.0)	844.0 (425.0 to 1660.0)	722.0 (323.0 to 1524.0)	315.0 (148.0 to 511.0)
CD4 dble_CD40L, Day 392	1130.5 (801.0 to 3108.5)	986.0 (340.0 to 1802.0)	660.0 (213.0 to 1706.0)	424.0 (239.0 to 645.0)
CD4 dble_IFN γ , Day 0	47.0 (4.0 to 391.0)	49.0 (1.0 to 352.0)	24.0 (1.0 to 118.0)	40.5 (1.0 to 681.0)
CD4 dble_IFN γ , Day 42	803.0 (260.0 to 1627.0)	406.0 (304.0 to 1481.0)	266.0 (206.0 to 394.0)	863.5 (352.5 to 1229.5)
CD4 dble_IFN γ , Day 385	200.0 (80.0 to 510.0)	316.5 (70.0 to 569.0)	248.5 (56.0 to 557.0)	589.5 (216.0 to 830.0)
CD4 dble_IFN γ , Day 392	459.5 (127.0 to 941.5)	329.0 (109.0 to 784.0)	123.0 (74.0 to 465.0)	423.5 (147.0 to 919.0)
CD4 dble_IL2, Day 0	89.5 (1.0 to 136.5)	72.0 (27.0 to 183.0)	50.0 (1.0 to 76.0)	47.0 (3.0 to 133.0)
CD4 dble_IL2, Day 42	3399.5 (1593.0 to 5907.0)	2438.0 (759.0 to 6212.0)	1344.0 (508.0 to 1859.0)	1448.0 (1012.5 to 2993.5)
CD4 dble_IL2, Day 385	1676.5 (779.5 to 2551.5)	1394.0 (531.0 to 2151.0)	1366.5 (460.0 to 1938.0)	870.5 (458.0 to 1223.0)
CD4 dble_IL2, Day 392	1502.5 (864.5 to 3500.0)	1455.0 (672.0 to 3065.0)	893.0 (627.0 to 1494.0)	840.0 (192.0 to 1067.0)
CD4 dble_TNF α , Day 0	49.5 (1.0 to 322.0)	98.0 (1.0 to 249.0)	62.0 (1.0 to 192.0)	52.0 (23.0 to 249.0)
CD4 dble_TNF α , Day 42	3023.0 (917.0 to 4946.0)	1970.0 (569.0 to 4382.0)	840.0 (705.0 to 1446.0)	1353.0 (723.0 to 2501.0)
CD4 dble_TNF α , Day 385	1339.0 (765.0 to 2419.5)	1233.0 (696.0 to 2030.0)	1277.5 (419.0 to 1921.0)	1097.5 (547.0 to 1517.0)

CD4 dble_TNFα, Day 392	1743.5 (741.5 to 3863.0)	1257.0 (504.0 to 2468.0)	740.0 (394.0 to 1266.0)	726.5 (433.0 to 1315.0)
CD8 dble_All (Polypositives), Day 0	3.5 (1.0 to 68.5)	5.0 (1.0 to 45.0)	30.0 (1.0 to 40.0)	47.0 (1.0 to 121.0)
CD8 dble_All (Polypositives), Day 42	48.0 (2.0 to 186.0)	63.0 (42.0 to 238.0)	45.0 (1.0 to 83.0)	125.0 (54.5 to 220.5)
CD8 dble_All (Polypositives), Day 385	33.5 (1.0 to 108.5)	62.5 (1.0 to 147.0)	1.0 (1.0 to 107.0)	56.0 (1.0 to 194.0)
CD8 dble_All (Polypositives), Day 392	63.0 (1.0 to 200.0)	33.0 (1.0 to 88.0)	25.0 (1.0 to 70.0)	60.5 (1.0 to 126.0)
CD8 dble_CD40L, Day 0	1.0 (1.0 to 72.5)	1.0 (1.0 to 21.0)	1.0 (1.0 to 37.0)	46.0 (1.0 to 75.0)
CD8 dble_CD40L, Day 42	108.0 (7.0 to 147.0)	25.0 (1.0 to 100.0)	1.0 (1.0 to 68.0)	7.5 (1.0 to 60.0)
CD8 dble_CD40L, Day 385	88.0 (1.0 to 197.5)	70.5 (11.0 to 132.0)	53.0 (1.0 to 93.0)	4.0 (1.0 to 116.0)
CD8 dble_CD40L, Day 392	40.0 (1.0 to 244.0)	18.0 (1.0 to 95.0)	14.0 (1.0 to 140.0)	80.0 (1.0 to 135.0)
CD8 dble_IFNγ, Day 0	41.5 (1.0 to 148.0)	33.0 (1.0 to 64.0)	22.0 (1.0 to 53.0)	78.0 (28.0 to 166.0)
CD8 dble_IFNγ, Day 42	32.0 (1.0 to 129.0)	77.0 (1.0 to 321.0)	67.0 (1.0 to 116.0)	191.5 (60.5 to 329.0)
CD8 dble_IFNγ, Day 385	99.5 (2.5 to 348.0)	103.0 (1.0 to 322.0)	31.0 (1.0 to 170.0)	165.5 (64.0 to 445.0)
CD8 dble_IFNγ, Day 392	52.0 (2.0 to 364.0)	174.0 (56.0 to 484.0)	31.0 (1.0 to 206.0)	119.0 (16.0 to 431.0)
CD8 dble_IL2, Day 0	1.0 (1.0 to 66.0)	22.0 (1.0 to 104.0)	1.0 (1.0 to 49.0)	1.0 (1.0 to 90.0)
CD8 dble_IL2, Day 42	1.0 (1.0 to 168.0)	48.0 (1.0 to 197.0)	53.0 (1.0 to 166.0)	65.5 (1.0 to 263.0)
CD8 dble_IL2, Day 385	1.0 (1.0 to 125.0)	32.5 (1.0 to 218.0)	16.0 (1.0 to 111.0)	14.0 (1.0 to 117.0)
CD8 dble_IL2, Day 392	63.0 (1.0 to 451.0)	99.0 (22.0 to 292.0)	1.0 (1.0 to 70.0)	64.0 (1.0 to 156.0)
CD8 dble_TNFα, Day 0	120.5 (1.0 to 553.0)	103.0 (1.0 to 516.0)	34.0 (1.0 to 324.0)	163.5 (48.0 to 614.0)
CD8 dble_TNFα, Day 42	192.0 (52.0 to 485.0)	396.0 (77.0 to 709.0)	125.0 (24.0 to 294.0)	351.5 (153.5 to 970.5)
CD8 dble_TNFα, Day 385	77.5 (15.0 to 477.5)	366.5 (1.0 to 559.0)	81.0 (1.0 to 204.0)	301.5 (29.0 to 641.0)
CD8 dble_TNFα, Day 392	217.0 (36.0 to 699.0)	130.0 (1.0 to 708.0)	121.0 (26.0 to 238.0)	310.0 (68.0 to 953.0)

End point values	H5N1 Formulation 5 Group			
Subject group type	Reporting group			
Number of subjects analysed	19			
Units: cells/million T cells				
median (inter-quartile range (Q1-Q3))				
CD4 dble_All (Polypositives), Day 0	74.0 (1.0 to 277.0)			
CD4 dble_All (Polypositives), Day 42	1372.5 (426.5 to 2911.5)			
CD4 dble_All (Polypositives), Day 385	596.0 (373.0 to 1167.0)			
CD4 dble_All (Polypositives), Day 392	832.0 (345.0 to 1497.0)			

CD4 dble_CD40L, Day 0	26.0 (1.0 to 133.0)			
CD4 dble_CD40L, Day 42	717.0 (295.5 to 1604.5)			
CD4 dble_CD40L, Day 385	588.0 (154.0 to 902.0)			
CD4 dble_CD40L, Day 392	325.0 (110.0 to 939.0)			
CD4 dble_IFN γ , Day 0	12.0 (1.0 to 259.0)			
CD4 dble_IFN γ , Day 42	437.5 (158.5 to 1027.0)			
CD4 dble_IFN γ , Day 385	163.0 (62.0 to 355.0)			
CD4 dble_IFN γ , Day 392	253.0 (112.0 to 608.0)			
CD4 dble_IL2, Day 0	75.0 (1.0 to 223.0)			
CD4 dble_IL2, Day 42	1761.5 (577.5 to 3085.5)			
CD4 dble_IL2, Day 385	621.0 (410.0 to 1556.0)			
CD4 dble_IL2, Day 392	882.0 (338.0 to 1181.0)			
CD4 dble_TNF α , Day 0	71.0 (29.0 to 296.0)			
CD4 dble_TNF α , Day 42	1204.5 (582.5 to 2853.0)			
CD4 dble_TNF α , Day 385	678.0 (463.0 to 1251.0)			
CD4 dble_TNF α , Day 392	908.0 (620.0 to 1579.0)			
CD8 dble_All (Polypositives), Day 0	1.0 (1.0 to 58.0)			
CD8 dble_All (Polypositives), Day 42	128.0 (10.0 to 323.0)			
CD8 dble_All (Polypositives), Day 385	1.0 (1.0 to 79.0)			
CD8 dble_All (Polypositives), Day 392	26.0 (1.0 to 99.0)			
CD8 dble_CD40L, Day 0	1.0 (1.0 to 57.0)			
CD8 dble_CD40L, Day 42	83.0 (1.0 to 186.0)			
CD8 dble_CD40L, Day 385	1.0 (1.0 to 31.0)			
CD8 dble_CD40L, Day 392	10.0 (1.0 to 55.0)			
CD8 dble_IFN γ , Day 0	1.0 (1.0 to 138.0)			
CD8 dble_IFN γ , Day 42	131.0 (1.0 to 243.0)			
CD8 dble_IFN γ , Day 385	1.0 (1.0 to 251.0)			
CD8 dble_IFN γ , Day 392	28.0 (1.0 to 366.0)			
CD8 dble_IL2, Day 0	1.0 (1.0 to 94.0)			
CD8 dble_IL2, Day 42	1.0 (1.0 to 186.0)			
CD8 dble_IL2, Day 385	1.0 (1.0 to 94.0)			

CD8 dble_IL2, Day 392	45.0 (1.0 to 77.0)			
CD8 dble_TNFα, Day 0	116.0 (1.0 to 521.0)			
CD8 dble_TNFα, Day 42	756.0 (65.0 to 1557.0)			
CD8 dble_TNFα, Day 385	212.0 (85.0 to 411.0)			
CD8 dble_TNFα, Day 392	207.0 (47.0 to 369.0)			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting solicited local symptoms

End point title	Number of subjects reporting solicited local symptoms
-----------------	---

End point description:

Solicited local AEs assessed were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = cried when limb is moved/spontaneously painful. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.

End point type	Secondary
----------------	-----------

End point timeframe:

During the 7-day follow-up period (i.e. on the day of vaccination and 6 subsequent days) after any vaccine dose

End point values	H5N1 Formulation 1 Group	H5N1 Formulation 2 Group	H5N1 Formulation 3 Group	H5N1 Formulation 4 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	38	37	38	37
Units: Participants				
Pain, Any	20	15	16	20
Pain, Grade 3	2	1	1	1
Redness (mm), Any	0	0	0	0
Redness (mm), Grade 3	0	0	0	0
Swelling (mm), Any	0	0	0	1
Swelling (mm), Grade 3	0	0	0	0

End point values	H5N1 Formulation 5 Group			
Subject group type	Reporting group			
Number of subjects analysed	35			
Units: Participants				
Pain, Any	17			
Pain, Grade 3	2			

Redness (mm), Any	0			
Redness (mm), Grade 3	0			
Swelling (mm), Any	0			
Swelling (mm), Grade 3	0			

Statistical analyses

No statistical analyses for this end point

Secondary: Duration of solicited local symptoms

End point title	Duration of solicited local symptoms
-----------------	--------------------------------------

End point description:

Duration was defined as number of days with any grade of local symptoms.

End point type	Secondary
----------------	-----------

End point timeframe:

During the 7-day follow-up period (i.e. on the day of vaccination and 6 subsequent days) after any vaccine dose

End point values	H5N1 Formulation 1 Group	H5N1 Formulation 2 Group	H5N1 Formulation 3 Group	H5N1 Formulation 4 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	38	37	38	37
Units: Days				
median (inter-quartile range (Q1-Q3))				
Pain, Dose 1	3.0 (1.0 to 4.0)	2.0 (1.0 to 3.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)
Pain, Dose 2	2.0 (1.0 to 3.0)	2.0 (1.0 to 2.0)	1.5 (1.0 to 2.0)	1.5 (1.0 to 2.0)
Pain, Dose 3	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 3.0)
Swelling, Dose 1	0.0 (0 to 0)	0.0 (0 to 0)	0.0 (0 to 0)	3.0 (3.0 to 3.0)

End point values	H5N1 Formulation 5 Group			
Subject group type	Reporting group			
Number of subjects analysed	35			
Units: Days				
median (inter-quartile range (Q1-Q3))				
Pain, Dose 1	1.0 (1.0 to 2.0)			
Pain, Dose 2	1.0 (1.0 to 2.5)			
Pain, Dose 3	1.5 (1.0 to 2.0)			
Swelling, Dose 1	0.0 (0 to 0)			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting solicited general symptoms.

End point title	Number of subjects reporting solicited general symptoms.
End point description:	
Assessed solicited general symptoms were fever (defined as temperature ≥ 38.0 degrees Celsius ($^{\circ}\text{C}$) assessed by any route (oral, axillary, rectal)], irritability/fussiness, drowsiness and. loss of appetite. Any = occurrence of the symptom regardless of intensity grade. Grade 3 irritability/Fussiness and Drowsiness = Prevented normal activity, Grade3 Loss of appetite = Did not eat at all. Grade 3 fever = fever > 40.0 $^{\circ}\text{C}$. Related = symptom assessed by the investigator as related to the vaccination	
End point type	Secondary
End point timeframe:	
During the 7-day follow-up period (i.e. on the day of vaccination and 6 subsequent days) after any vaccine dose	

End point values	H5N1 Formulation 1 Group	H5N1 Formulation 2 Group	H5N1 Formulation 3 Group	H5N1 Formulation 4 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	38	37	38	37
Units: Participants				
Drowsiness, Any	25	18	13	17
Drowsiness, Grade 3	2	3	1	1
Drowsiness, Related	22	14	12	13
Irritability / Fussiness, Any	24	17	19	22
Irritability / Fussiness, Grade 3	3	2	3	2
Irritability / Fussiness, Related	22	14	17	16
Loss Of Appetite, Any	24	13	14	20
Loss Of Appetite, Grade 3	0	1	2	2
Loss Of Appetite, Related	21	7	11	15
Temperature/(Axillary) ($^{\circ}\text{C}$), Any	24	17	14	14
Temperature/(Axillary) ($^{\circ}\text{C}$), Grade 3	0	0	1	0
Temperature/(Axillary) ($^{\circ}\text{C}$), Related	22	12	12	14

End point values	H5N1 Formulation 5 Group			
Subject group type	Reporting group			
Number of subjects analysed	35			
Units: Participants				
Drowsiness, Any	16			
Drowsiness, Grade 3	0			
Drowsiness, Related	14			
Irritability / Fussiness, Any	21			
Irritability / Fussiness, Grade 3	0			
Irritability / Fussiness, Related	19			
Loss Of Appetite, Any	13			

Loss Of Appetite, Grade 3	0			
Loss Of Appetite, Related	10			
Temperature/(Axillary) (°C), Any	10			
Temperature/(Axillary) (°C), Grade 3	0			
Temperature/(Axillary) (°C), Related	10			

Statistical analyses

No statistical analyses for this end point

Secondary: Duration of solicited general symptoms.

End point title	Duration of solicited general symptoms.
-----------------	---

End point description:

Duration was defined as number of days with any grade of general symptoms.

End point type	Secondary
----------------	-----------

End point timeframe:

During the 7-day follow-up period (i.e. on the day of vaccination and 6 subsequent days) after any vaccine dose

End point values	H5N1 Formulation 1 Group	H5N1 Formulation 2 Group	H5N1 Formulation 3 Group	H5N1 Formulation 4 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	38	37	38	37
Units: Days				
median (inter-quartile range (Q1-Q3))				
Drowsiness, Dose 1	2.0 (1.0 to 3.0)	1.5 (1.0 to 3.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 3.0)
Drowsiness, Dose 2	1.0 (1.0 to 2.0)	2.0 (1.0 to 2.5)	2.0 (2.0 to 3.5)	2.0 (1.0 to 2.0)
Drowsiness, Dose 3	2.0 (1.0 to 2.0)	2.0 (2.0 to 2.0)	2.0 (2.0 to 2.0)	2.5 (1.0 to 4.0)
Irritability / fussiness, Dose 1	2.0 (1.0 to 3.0)	2.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	2.0 (1.0 to 4.0)
Irritability / fussiness, Dose 2	2.0 (1.0 to 3.0)	2.0 (1.0 to 3.0)	2.0 (1.0 to 4.0)	2.0 (1.0 to 4.0)
Irritability / fussiness, Dose 3	2.0 (2.0 to 3.0)	3.0 (2.0 to 3.0)	1.0 (1.0 to 2.0)	4.0 (3.0 to 5.0)
Loss of appetite, Dose 1	2.0 (1.0 to 2.5)	3.0 (3.0 to 3.0)	2.0 (1.0 to 3.0)	2.5 (2.0 to 5.0)
Loss of appetite, Dose 2	2.0 (1.0 to 6.0)	2.0 (1.0 to 2.0)	3.0 (2.0 to 4.0)	2.0 (1.0 to 3.0)
Loss of appetite, Dose 3	2.0 (1.0 to 3.5)	2.5 (1.5 to 4.5)	2.0 (1.5 to 3.0)	3.0 (2.0 to 4.0)
Temperature, Dose 1	1.0 (1.0 to 1.0)	2.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	2.0 (1.0 to 4.0)
Temperature, Dose 2	1.0 (1.0 to 3.0)	1.0 (1.0 to 1.5)	1.0 (1.0 to 1.0)	1.0 (1.0 to 1.5)
Temperature, Dose 3	1.0 (1.0 to 1.5)	2.0 (1.0 to 3.0)	1.0 (1.0 to 1.0)	3.0 (2.0 to 4.0)

End point values	H5N1 Formulation 5 Group			
Subject group type	Reporting group			
Number of subjects analysed	35			
Units: Days				

median (inter-quartile range (Q1-Q3))				
Drowsiness, Dose 1	1.0 (1.0 to 2.0)			
Drowsiness, Dose 2	1.5 (1.0 to 2.0)			
Drowsiness, Dose 3	1.0 (1.0 to 3.0)			
Irritability / fussiness, Dose 1	2.0 (1.0 to 2.0)			
Irritability / fussiness, Dose 2	2.0 (1.0 to 3.0)			
Irritability / fussiness, Dose 3	1.5 (1.0 to 3.0)			
Loss of appetite, Dose 1	1.5 (1.0 to 2.5)			
Loss of appetite, Dose 2	2.0 (1.0 to 3.0)			
Loss of appetite, Dose 3	2.0 (1.0 to 3.0)			
Temperature, Dose 1	1.0 (1.0 to 1.0)			
Temperature, Dose 2	1.0 (1.0 to 1.0)			
Temperature, Dose 3	0.0 (0.0 to 0.0)			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any unsolicited adverse events (AEs) post primary vaccination.

End point title	Number of subjects reporting any unsolicited adverse events (AEs) post primary vaccination.
-----------------	---

End point description:

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevents normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

End point type	Secondary
----------------	-----------

End point timeframe:

During the 21-day follow-up period (Day 0-Day 20) after each vaccine dose

End point values	H5N1 Formulation 1 Group	H5N1 Formulation 2 Group	H5N1 Formulation 3 Group	H5N1 Formulation 4 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	38	37	38	37
Units: Participants				
Any	21	20	23	20
Grade 3	3	1	1	3
Related	2	0	1	1

End point values	H5N1 Formulation 5 Group			
------------------	--------------------------------	--	--	--

Subject group type	Reporting group			
Number of subjects analysed	35			
Units: Participants				
Any	21			
Grade 3	5			
Related	3			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any unsolicited adverse events (AEs) post booster vaccination

End point title	Number of subjects reporting any unsolicited adverse events (AEs) post booster vaccination
-----------------	--

End point description:

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevents normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

End point type	Secondary
----------------	-----------

End point timeframe:

During the 30-day (Day 385-Day 415) follow-up period after vaccination

End point values	H5N1 Formulation 1 Group	H5N1 Formulation 2 Group	H5N1 Formulation 3 Group	H5N1 Formulation 4 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	36	34	38	35
Units: Participants				
Any	16	8	16	19
Grade 3	1	0	0	1
Related	1	0	1	0

End point values	H5N1 Formulation 5 Group			
Subject group type	Reporting group			
Number of subjects analysed	33			
Units: Participants				
Any	14			
Grade 3	0			
Related	0			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting Medically attended events (MAEs)

End point title	Number of subjects reporting Medically attended events (MAEs)
-----------------	---

End point description:

MAEs are adverse events with medically-attended visits that were not routine visits for physical examination or vaccination. Any MAE was defined as at least 1 MAE experienced.

End point type	Secondary
----------------	-----------

End point timeframe:

During the entire study period (Day 0 to Day 415 approximately)

End point values	H5N1 Formulation 1 Group	H5N1 Formulation 2 Group	H5N1 Formulation 3 Group	H5N1 Formulation 4 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	38	37	38	37
Units: Participants				
Any	29	28	33	27
Related	1	0	0	1

End point values	H5N1 Formulation 5 Group			
Subject group type	Reporting group			
Number of subjects analysed	35			
Units: Participants				
Any	26			
Related	0			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting Potential immune mediated diseases (pIMDs)

End point title	Number of subjects reporting Potential immune mediated diseases (pIMDs)
-----------------	---

End point description:

Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. "Any pIMD" = at least one pIMD experienced by the study subject. Related = pIMD assessed by the investigator to be causally related to the study vaccination.

End point type	Secondary
----------------	-----------

End point timeframe:

During the entire study period (Day 0 to Day 415 approximately)

End point values	H5N1 Formulation 1 Group	H5N1 Formulation 2 Group	H5N1 Formulation 3 Group	H5N1 Formulation 4 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	38	37	38	37
Units: Participants				
Any	0	0	1	0
Related	0	0	0	0

End point values	H5N1 Formulation 5 Group			
Subject group type	Reporting group			
Number of subjects analysed	35			
Units: Participants				
Any	0			
Related	0			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting Serious adverse events (SAEs)

End point title	Number of subjects reporting Serious adverse events (SAEs)
-----------------	--

End point description:

A serious adverse event was defined as any untoward medical occurrence that: resulted in death, was life threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity or was a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination.

End point type	Secondary
----------------	-----------

End point timeframe:

During the entire study period (Day 0 to Day 415 approximately)

End point values	H5N1 Formulation 1 Group	H5N1 Formulation 2 Group	H5N1 Formulation 3 Group	H5N1 Formulation 4 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	38	37	38	37
Units: Participants				
Any	5	6	10	4
Related	0	0	0	0

End point values	H5N1 Formulation 5 Group			
Subject group type	Reporting group			
Number of subjects analysed	35			
Units: Participants				
Any	4			
Related	0			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting Adverse events of special interest (AESI)

End point title	Number of subjects reporting Adverse events of special interest (AESI)
-----------------	--

End point description:

AESI are a subset of adverse events defined in the Committee for Medicinal Products for Human Use (CHMP) Risk Management Plan for Pandemic Vaccines for safety monitoring.

End point type	Secondary
----------------	-----------

End point timeframe:

During the entire study period (Day 0 to Day 415 approximately)

End point values	H5N1 Formulation 1 Group	H5N1 Formulation 2 Group	H5N1 Formulation 3 Group	H5N1 Formulation 4 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	38	37	38	37
Units: Participants				
Any	4	3	3	2
Related	1	0	1	1

End point values	H5N1 Formulation 5 Group			
------------------	--------------------------------	--	--	--

Subject group type	Reporting group			
Number of subjects analysed	35			
Units: Participants				
Any	2			
Related	0			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Solicited local and general AEs: during 7-day follow-up period after any vaccine dose. Unsolicited AEs: Days 0-20 after each primary dose and Days 385-415 post booster dose. MAEs, pIMDs, SAEs, AESI: during the entire study period (Days 0-415 approximately).

Adverse event reporting additional description:

The analysis was performed solely on vaccinated subjects with symptom sheet completed for the reported specific symptom.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	21.0
--------------------	------

Reporting groups

Reporting group title	H5N1 Formulation 2 Group
-----------------------	--------------------------

Reporting group description:

Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 2 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered IM in anterolateral thigh.

Reporting group title	H5N1 Formulation 1 Group
-----------------------	--------------------------

Reporting group description:

Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 1 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered intramuscularly (IM) in anterolateral thigh.

Reporting group title	H5N1 Formulation 4 Group
-----------------------	--------------------------

Reporting group description:

Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 4 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered IM in anterolateral thigh.

Reporting group title	H5N1 Formulation 3 Group
-----------------------	--------------------------

Reporting group description:

Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 3 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered IM in anterolateral thigh.

Reporting group title	H5N1 Formulation 5 Group
-----------------------	--------------------------

Reporting group description:

Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 5 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered IM in anterolateral thigh.

Serious adverse events	H5N1 Formulation 2 Group	H5N1 Formulation 1 Group	H5N1 Formulation 4 Group
Total subjects affected by serious adverse events			
subjects affected / exposed	6 / 37 (16.22%)	5 / 38 (13.16%)	4 / 37 (10.81%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Injury, poisoning and procedural complications			
Lower limb fracture			

subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	0 / 37 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Kawasaki's disease			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	0 / 37 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Febrile convulsion			
subjects affected / exposed	1 / 37 (2.70%)	1 / 38 (2.63%)	0 / 37 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal hernia			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	0 / 37 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	1 / 37 (2.70%)	0 / 38 (0.00%)	0 / 37 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Balanoposthitis			
subjects affected / exposed	0 / 37 (0.00%)	1 / 38 (2.63%)	0 / 37 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Bacteraemia			
subjects affected / exposed	0 / 37 (0.00%)	1 / 38 (2.63%)	0 / 37 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacterial infection			

subjects affected / exposed	1 / 37 (2.70%)	1 / 38 (2.63%)	0 / 37 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchiolitis			
subjects affected / exposed	1 / 37 (2.70%)	0 / 38 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	1 / 37 (2.70%)	1 / 38 (2.63%)	0 / 37 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Conjunctivitis			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	0 / 37 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Croup infectious			
subjects affected / exposed	1 / 37 (2.70%)	1 / 38 (2.63%)	0 / 37 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea infectious			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	0 / 37 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpangina			
subjects affected / exposed	1 / 37 (2.70%)	1 / 38 (2.63%)	0 / 37 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			

subjects affected / exposed	1 / 37 (2.70%)	1 / 38 (2.63%)	0 / 37 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nasopharyngitis			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oral herpes			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	0 / 37 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	2 / 37 (5.41%)	0 / 38 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia respiratory syncytial viral			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	0 / 37 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia viral			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	0 / 37 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus bronchiolitis			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	0 / 37 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus bronchitis			
subjects affected / exposed	0 / 37 (0.00%)	1 / 38 (2.63%)	0 / 37 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus infection			

subjects affected / exposed	0 / 37 (0.00%)	1 / 38 (2.63%)	0 / 37 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Scarlet fever			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	0 / 37 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinusitis			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	0 / 37 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsillitis			
subjects affected / exposed	0 / 37 (0.00%)	1 / 38 (2.63%)	0 / 37 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	0 / 37 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Varicella			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	0 / 37 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	1 / 37 (2.70%)	0 / 38 (0.00%)	0 / 37 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral rash			
subjects affected / exposed	1 / 37 (2.70%)	0 / 38 (0.00%)	0 / 37 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral upper respiratory tract infection			

subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	0 / 37 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	H5N1 Formulation 3 Group	H5N1 Formulation 5 Group	
Total subjects affected by serious adverse events			
subjects affected / exposed	10 / 38 (26.32%)	4 / 35 (11.43%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events			
Injury, poisoning and procedural complications			
Lower limb fracture			
subjects affected / exposed	0 / 38 (0.00%)	1 / 35 (2.86%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Kawasaki's disease			
subjects affected / exposed	1 / 38 (2.63%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Febrile convulsion			
subjects affected / exposed	1 / 38 (2.63%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal hernia			
subjects affected / exposed	1 / 38 (2.63%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			
subjects affected / exposed	0 / 38 (0.00%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			

Balanoposthitis			
subjects affected / exposed	0 / 38 (0.00%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Bacteraemia			
subjects affected / exposed	0 / 38 (0.00%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterial infection			
subjects affected / exposed	0 / 38 (0.00%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchiolitis			
subjects affected / exposed	1 / 38 (2.63%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis			
subjects affected / exposed	1 / 38 (2.63%)	1 / 35 (2.86%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Conjunctivitis			
subjects affected / exposed	1 / 38 (2.63%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Croup infectious			
subjects affected / exposed	0 / 38 (0.00%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea infectious			
subjects affected / exposed	1 / 38 (2.63%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis			

subjects affected / exposed	3 / 38 (7.89%)	1 / 35 (2.86%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpangina			
subjects affected / exposed	0 / 38 (0.00%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza			
subjects affected / exposed	0 / 38 (0.00%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nasopharyngitis			
subjects affected / exposed	0 / 38 (0.00%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oral herpes			
subjects affected / exposed	1 / 38 (2.63%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	3 / 38 (7.89%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia respiratory syncytial viral			
subjects affected / exposed	0 / 38 (0.00%)	1 / 35 (2.86%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia viral			
subjects affected / exposed	1 / 38 (2.63%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory syncytial virus bronchiolitis			

subjects affected / exposed	1 / 38 (2.63%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory syncytial virus bronchitis			
subjects affected / exposed	0 / 38 (0.00%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory syncytial virus infection			
subjects affected / exposed	2 / 38 (5.26%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Scarlet fever			
subjects affected / exposed	2 / 38 (5.26%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinusitis			
subjects affected / exposed	1 / 38 (2.63%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tonsillitis			
subjects affected / exposed	0 / 38 (0.00%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper respiratory tract infection			
subjects affected / exposed	1 / 38 (2.63%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Varicella			
subjects affected / exposed	1 / 38 (2.63%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral infection			

subjects affected / exposed	1 / 38 (2.63%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral rash			
subjects affected / exposed	0 / 38 (0.00%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 38 (0.00%)	1 / 35 (2.86%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	H5N1 Formulation 2 Group	H5N1 Formulation 1 Group	H5N1 Formulation 4 Group
Total subjects affected by non-serious adverse events			
subjects affected / exposed	31 / 37 (83.78%)	36 / 38 (94.74%)	35 / 37 (94.59%)
General disorders and administration site conditions			
Feeling hot			
subjects affected / exposed	0 / 37 (0.00%)	2 / 38 (5.26%)	1 / 37 (2.70%)
occurrences (all)	0	4	1
Influenza like illness			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	1 / 37 (2.70%)
occurrences (all)	0	0	1
Injection site erythema			
subjects affected / exposed	0 / 37 (0.00%)	1 / 38 (2.63%)	0 / 37 (0.00%)
occurrences (all)	0	1	0
Injection site urticaria			
subjects affected / exposed	0 / 37 (0.00%)	1 / 38 (2.63%)	0 / 37 (0.00%)
occurrences (all)	0	1	0
Pain			
subjects affected / exposed	15 / 37 (40.54%)	20 / 38 (52.63%)	20 / 37 (54.05%)
occurrences (all)	32	39	31
Pyrexia			

subjects affected / exposed	17 / 37 (45.95%)	24 / 38 (63.16%)	16 / 37 (43.24%)
occurrences (all)	21	36	20
Swelling			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	1 / 37 (2.70%)
occurrences (all)	0	0	1
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	0 / 37 (0.00%)
occurrences (all)	0	0	0
Bronchial hyperreactivity			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	1 / 37 (2.70%)
occurrences (all)	0	0	1
Cough			
subjects affected / exposed	2 / 37 (5.41%)	0 / 38 (0.00%)	3 / 37 (8.11%)
occurrences (all)	2	0	3
Increased upper airway secretion			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	1 / 37 (2.70%)
occurrences (all)	0	0	1
Oropharyngeal pain			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	0 / 37 (0.00%)
occurrences (all)	0	0	0
Productive cough			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	0 / 37 (0.00%)
occurrences (all)	0	0	0
Respiration abnormal			
subjects affected / exposed	1 / 37 (2.70%)	0 / 38 (0.00%)	0 / 37 (0.00%)
occurrences (all)	1	0	0
Rhinitis allergic			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	0 / 37 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
subjects affected / exposed	2 / 37 (5.41%)	1 / 38 (2.63%)	1 / 37 (2.70%)
occurrences (all)	3	1	3
Psychiatric disorders			

Irritability subjects affected / exposed occurrences (all)	17 / 37 (45.95%) 26	24 / 38 (63.16%) 39	22 / 37 (59.46%) 35
Product issues Device breakage subjects affected / exposed occurrences (all)	0 / 37 (0.00%) 0	0 / 38 (0.00%) 0	0 / 37 (0.00%) 0
Investigations Body height below normal subjects affected / exposed occurrences (all) Body temperature increased subjects affected / exposed occurrences (all) Cardiac murmur subjects affected / exposed occurrences (all)	0 / 37 (0.00%) 0 0 / 37 (0.00%) 0 0 / 37 (0.00%) 0	1 / 38 (2.63%) 1 1 / 38 (2.63%) 1 0 / 38 (0.00%) 0	0 / 37 (0.00%) 0 1 / 37 (2.70%) 1 0 / 37 (0.00%) 0
Injury, poisoning and procedural complications Arthropod bite subjects affected / exposed occurrences (all) Contusion subjects affected / exposed occurrences (all) Forearm fracture subjects affected / exposed occurrences (all) Foreign body in eye subjects affected / exposed occurrences (all) Head injury subjects affected / exposed occurrences (all) Limb injury subjects affected / exposed occurrences (all)	0 / 37 (0.00%) 0 1 / 37 (2.70%) 1 0 / 37 (0.00%) 0 0 / 37 (0.00%) 0 0 / 37 (0.00%) 0 0 / 37 (0.00%) 0	1 / 38 (2.63%) 1 0 / 38 (0.00%) 0 0 / 38 (0.00%) 0 0 / 38 (0.00%) 0 0 / 38 (0.00%) 0 1 / 38 (2.63%) 1	0 / 37 (0.00%) 0 0 / 37 (0.00%) 0 0 / 37 (0.00%) 0 0 / 37 (0.00%) 0 0 / 37 (0.00%) 0

Skin abrasion subjects affected / exposed occurrences (all)	1 / 37 (2.70%) 1	0 / 38 (0.00%) 0	0 / 37 (0.00%) 0
Nervous system disorders			
Febrile convulsion subjects affected / exposed occurrences (all)	0 / 37 (0.00%) 0	0 / 38 (0.00%) 0	1 / 37 (2.70%) 1
Headache subjects affected / exposed occurrences (all)	0 / 37 (0.00%) 0	0 / 38 (0.00%) 0	0 / 37 (0.00%) 0
Somnolence subjects affected / exposed occurrences (all)	18 / 37 (48.65%) 29	25 / 38 (65.79%) 42	17 / 37 (45.95%) 29
Speech disorder developmental subjects affected / exposed occurrences (all)	0 / 37 (0.00%) 0	1 / 38 (2.63%) 1	0 / 37 (0.00%) 0
Blood and lymphatic system disorders			
Anaemia subjects affected / exposed occurrences (all)	0 / 37 (0.00%) 0	1 / 38 (2.63%) 1	0 / 37 (0.00%) 0
Iron deficiency anaemia subjects affected / exposed occurrences (all)	0 / 37 (0.00%) 0	0 / 38 (0.00%) 0	1 / 37 (2.70%) 1
Eye disorders			
Erythema of eyelid subjects affected / exposed occurrences (all)	0 / 37 (0.00%) 0	0 / 38 (0.00%) 0	0 / 37 (0.00%) 0
Eyelid oedema subjects affected / exposed occurrences (all)	0 / 37 (0.00%) 0	0 / 38 (0.00%) 0	0 / 37 (0.00%) 0
Periorbital oedema subjects affected / exposed occurrences (all)	0 / 37 (0.00%) 0	0 / 38 (0.00%) 0	0 / 37 (0.00%) 0
Gastrointestinal disorders			
Abdominal discomfort subjects affected / exposed occurrences (all)	1 / 37 (2.70%) 1	0 / 38 (0.00%) 0	0 / 37 (0.00%) 0

Abdominal pain			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	1 / 37 (2.70%)
occurrences (all)	0	0	1
Constipation			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	0 / 37 (0.00%)
occurrences (all)	0	0	0
Diarrhoea			
subjects affected / exposed	2 / 37 (5.41%)	2 / 38 (5.26%)	2 / 37 (5.41%)
occurrences (all)	2	2	2
Flatulence			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	0 / 37 (0.00%)
occurrences (all)	0	0	0
Food poisoning			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	0 / 37 (0.00%)
occurrences (all)	0	0	0
Gastritis			
subjects affected / exposed	0 / 37 (0.00%)	1 / 38 (2.63%)	0 / 37 (0.00%)
occurrences (all)	0	1	0
Gastrointestinal inflammation			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	0 / 37 (0.00%)
occurrences (all)	0	0	0
Mouth ulceration			
subjects affected / exposed	0 / 37 (0.00%)	1 / 38 (2.63%)	0 / 37 (0.00%)
occurrences (all)	0	1	0
Vomiting			
subjects affected / exposed	0 / 37 (0.00%)	3 / 38 (7.89%)	2 / 37 (5.41%)
occurrences (all)	0	3	2
Skin and subcutaneous tissue disorders			
Blister			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	0 / 37 (0.00%)
occurrences (all)	0	0	0
Dermatitis allergic			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	1 / 37 (2.70%)
occurrences (all)	0	0	1
Dermatitis atopic			

subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	0 / 37 (0.00%)
occurrences (all)	0	0	0
Dermatitis diaper			
subjects affected / exposed	1 / 37 (2.70%)	2 / 38 (5.26%)	0 / 37 (0.00%)
occurrences (all)	1	2	0
Eczema			
subjects affected / exposed	0 / 37 (0.00%)	1 / 38 (2.63%)	0 / 37 (0.00%)
occurrences (all)	0	1	0
Erythema			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	0 / 37 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	1 / 37 (2.70%)
occurrences (all)	0	0	1
Rash generalised			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	1 / 37 (2.70%)
occurrences (all)	0	0	1
Rash papular			
subjects affected / exposed	0 / 37 (0.00%)	1 / 38 (2.63%)	0 / 37 (0.00%)
occurrences (all)	0	1	0
Urticaria			
subjects affected / exposed	1 / 37 (2.70%)	1 / 38 (2.63%)	1 / 37 (2.70%)
occurrences (all)	1	1	1
Infections and infestations			
Acute sinusitis			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	0 / 37 (0.00%)
occurrences (all)	0	0	0
Bronchiolitis			
subjects affected / exposed	1 / 37 (2.70%)	0 / 38 (0.00%)	2 / 37 (5.41%)
occurrences (all)	1	0	2
Bronchitis			
subjects affected / exposed	2 / 37 (5.41%)	2 / 38 (5.26%)	0 / 37 (0.00%)
occurrences (all)	2	2	0
Bronchitis viral			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	1 / 37 (2.70%)
occurrences (all)	0	0	1

Candida infection			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	0 / 37 (0.00%)
occurrences (all)	0	0	0
Cellulitis			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	0 / 37 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	2 / 37 (5.41%)	0 / 38 (0.00%)	0 / 37 (0.00%)
occurrences (all)	3	0	0
Enterovirus infection			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	0 / 37 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis			
subjects affected / exposed	2 / 37 (5.41%)	1 / 38 (2.63%)	0 / 37 (0.00%)
occurrences (all)	3	1	0
Gastroenteritis viral			
subjects affected / exposed	0 / 37 (0.00%)	2 / 38 (5.26%)	0 / 37 (0.00%)
occurrences (all)	0	2	0
Hand-foot-and-mouth disease			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	1 / 37 (2.70%)
occurrences (all)	0	0	1
Hordeolum			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	0 / 37 (0.00%)
occurrences (all)	0	0	0
Impetigo			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	0 / 37 (0.00%)
occurrences (all)	0	0	0
Influenza			
subjects affected / exposed	0 / 37 (0.00%)	1 / 38 (2.63%)	0 / 37 (0.00%)
occurrences (all)	0	1	0
Nasopharyngitis			
subjects affected / exposed	8 / 37 (21.62%)	10 / 38 (26.32%)	5 / 37 (13.51%)
occurrences (all)	10	13	6
Oral herpes			
subjects affected / exposed	1 / 37 (2.70%)	0 / 38 (0.00%)	0 / 37 (0.00%)
occurrences (all)	1	0	0

Otitis media			
subjects affected / exposed	0 / 37 (0.00%)	1 / 38 (2.63%)	0 / 37 (0.00%)
occurrences (all)	0	1	0
Otitis media acute			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	1 / 37 (2.70%)
occurrences (all)	0	0	1
Paronychia			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	0 / 37 (0.00%)
occurrences (all)	0	0	0
Pharyngitis			
subjects affected / exposed	1 / 37 (2.70%)	3 / 38 (7.89%)	1 / 37 (2.70%)
occurrences (all)	1	6	1
Pharyngotonsillitis			
subjects affected / exposed	1 / 37 (2.70%)	0 / 38 (0.00%)	0 / 37 (0.00%)
occurrences (all)	1	0	0
Pneumonia			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	1 / 37 (2.70%)
occurrences (all)	0	0	1
Respiratory syncytial virus bronchitis			
subjects affected / exposed	0 / 37 (0.00%)	1 / 38 (2.63%)	0 / 37 (0.00%)
occurrences (all)	0	1	0
Roseola			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	0 / 37 (0.00%)
occurrences (all)	0	0	0
Sinusitis			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	0 / 37 (0.00%)
occurrences (all)	0	0	0
Tonsillitis			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	0 / 37 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	8 / 37 (21.62%)	7 / 38 (18.42%)	13 / 37 (35.14%)
occurrences (all)	10	7	16
Viral diarrhoea			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	1 / 37 (2.70%)
occurrences (all)	0	0	1

Viral infection			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	1 / 37 (2.70%)
occurrences (all)	0	0	1
Viral rash			
subjects affected / exposed	0 / 37 (0.00%)	3 / 38 (7.89%)	0 / 37 (0.00%)
occurrences (all)	0	3	0
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	1 / 37 (2.70%)
occurrences (all)	0	0	1
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	13 / 37 (35.14%)	25 / 38 (65.79%)	20 / 37 (54.05%)
occurrences (all)	16	39	30
Failure to thrive			
subjects affected / exposed	0 / 37 (0.00%)	0 / 38 (0.00%)	0 / 37 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	H5N1 Formulation 3 Group	H5N1 Formulation 5 Group	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	35 / 38 (92.11%)	32 / 35 (91.43%)	
General disorders and administration site conditions			
Feeling hot			
subjects affected / exposed	3 / 38 (7.89%)	0 / 35 (0.00%)	
occurrences (all)	3	0	
Influenza like illness			
subjects affected / exposed	0 / 38 (0.00%)	0 / 35 (0.00%)	
occurrences (all)	0	0	
Injection site erythema			
subjects affected / exposed	0 / 38 (0.00%)	0 / 35 (0.00%)	
occurrences (all)	0	0	
Injection site urticaria			
subjects affected / exposed	0 / 38 (0.00%)	0 / 35 (0.00%)	
occurrences (all)	0	0	
Pain			
subjects affected / exposed	16 / 38 (42.11%)	17 / 35 (48.57%)	
occurrences (all)	31	36	

Pyrexia			
subjects affected / exposed	15 / 38 (39.47%)	12 / 35 (34.29%)	
occurrences (all)	16	15	
Swelling			
subjects affected / exposed	0 / 38 (0.00%)	0 / 35 (0.00%)	
occurrences (all)	0	0	
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	1 / 38 (2.63%)	0 / 35 (0.00%)	
occurrences (all)	1	0	
Bronchial hyperreactivity			
subjects affected / exposed	0 / 38 (0.00%)	0 / 35 (0.00%)	
occurrences (all)	0	0	
Cough			
subjects affected / exposed	2 / 38 (5.26%)	1 / 35 (2.86%)	
occurrences (all)	2	2	
Increased upper airway secretion			
subjects affected / exposed	0 / 38 (0.00%)	0 / 35 (0.00%)	
occurrences (all)	0	0	
Oropharyngeal pain			
subjects affected / exposed	1 / 38 (2.63%)	0 / 35 (0.00%)	
occurrences (all)	1	0	
Productive cough			
subjects affected / exposed	0 / 38 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Respiration abnormal			
subjects affected / exposed	0 / 38 (0.00%)	0 / 35 (0.00%)	
occurrences (all)	0	0	
Rhinitis allergic			
subjects affected / exposed	1 / 38 (2.63%)	1 / 35 (2.86%)	
occurrences (all)	1	1	
Rhinorrhoea			
subjects affected / exposed	5 / 38 (13.16%)	2 / 35 (5.71%)	
occurrences (all)	7	2	
Psychiatric disorders			

Irritability subjects affected / exposed occurrences (all)	19 / 38 (50.00%) 31	21 / 35 (60.00%) 38	
Product issues Device breakage subjects affected / exposed occurrences (all)	1 / 38 (2.63%) 1	0 / 35 (0.00%) 0	
Investigations Body height below normal subjects affected / exposed occurrences (all) Body temperature increased subjects affected / exposed occurrences (all) Cardiac murmur subjects affected / exposed occurrences (all)	0 / 38 (0.00%) 0 2 / 38 (5.26%) 2 1 / 38 (2.63%) 1	0 / 35 (0.00%) 0 1 / 35 (2.86%) 1 0 / 35 (0.00%) 0	
Injury, poisoning and procedural complications Arthropod bite subjects affected / exposed occurrences (all) Contusion subjects affected / exposed occurrences (all) Forearm fracture subjects affected / exposed occurrences (all) Foreign body in eye subjects affected / exposed occurrences (all) Head injury subjects affected / exposed occurrences (all) Limb injury subjects affected / exposed occurrences (all)	0 / 38 (0.00%) 0 0 / 38 (0.00%) 0 1 / 38 (2.63%) 1 1 / 38 (2.63%) 1 0 / 38 (0.00%) 0 0 / 38 (0.00%) 0	1 / 35 (2.86%) 1 0 / 35 (0.00%) 0 0 / 35 (0.00%) 0 0 / 35 (0.00%) 0 1 / 35 (2.86%) 1 0 / 35 (0.00%) 0	

Skin abrasion subjects affected / exposed occurrences (all)	0 / 38 (0.00%) 0	0 / 35 (0.00%) 0	
Nervous system disorders Febrile convulsion subjects affected / exposed occurrences (all)	0 / 38 (0.00%) 0	0 / 35 (0.00%) 0	
Headache subjects affected / exposed occurrences (all)	0 / 38 (0.00%) 0	1 / 35 (2.86%) 1	
Somnolence subjects affected / exposed occurrences (all)	13 / 38 (34.21%) 20	16 / 35 (45.71%) 24	
Speech disorder developmental subjects affected / exposed occurrences (all)	0 / 38 (0.00%) 0	0 / 35 (0.00%) 0	
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	0 / 38 (0.00%) 0	0 / 35 (0.00%) 0	
Iron deficiency anaemia subjects affected / exposed occurrences (all)	0 / 38 (0.00%) 0	0 / 35 (0.00%) 0	
Eye disorders Erythema of eyelid subjects affected / exposed occurrences (all)	0 / 38 (0.00%) 0	1 / 35 (2.86%) 1	
Eyelid oedema subjects affected / exposed occurrences (all)	0 / 38 (0.00%) 0	1 / 35 (2.86%) 1	
Periorbital oedema subjects affected / exposed occurrences (all)	1 / 38 (2.63%) 1	0 / 35 (0.00%) 0	
Gastrointestinal disorders Abdominal discomfort subjects affected / exposed occurrences (all)	0 / 38 (0.00%) 0	0 / 35 (0.00%) 0	

Abdominal pain			
subjects affected / exposed	0 / 38 (0.00%)	0 / 35 (0.00%)	
occurrences (all)	0	0	
Constipation			
subjects affected / exposed	0 / 38 (0.00%)	2 / 35 (5.71%)	
occurrences (all)	0	2	
Diarrhoea			
subjects affected / exposed	1 / 38 (2.63%)	3 / 35 (8.57%)	
occurrences (all)	1	3	
Flatulence			
subjects affected / exposed	0 / 38 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Food poisoning			
subjects affected / exposed	1 / 38 (2.63%)	0 / 35 (0.00%)	
occurrences (all)	1	0	
Gastritis			
subjects affected / exposed	0 / 38 (0.00%)	0 / 35 (0.00%)	
occurrences (all)	0	0	
Gastrointestinal inflammation			
subjects affected / exposed	1 / 38 (2.63%)	0 / 35 (0.00%)	
occurrences (all)	1	0	
Mouth ulceration			
subjects affected / exposed	1 / 38 (2.63%)	1 / 35 (2.86%)	
occurrences (all)	1	1	
Vomiting			
subjects affected / exposed	1 / 38 (2.63%)	3 / 35 (8.57%)	
occurrences (all)	1	3	
Skin and subcutaneous tissue disorders			
Blister			
subjects affected / exposed	0 / 38 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Dermatitis allergic			
subjects affected / exposed	0 / 38 (0.00%)	0 / 35 (0.00%)	
occurrences (all)	0	0	
Dermatitis atopic			

subjects affected / exposed	0 / 38 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Dermatitis diaper			
subjects affected / exposed	1 / 38 (2.63%)	1 / 35 (2.86%)	
occurrences (all)	1	1	
Eczema			
subjects affected / exposed	0 / 38 (0.00%)	0 / 35 (0.00%)	
occurrences (all)	0	0	
Erythema			
subjects affected / exposed	0 / 38 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Rash			
subjects affected / exposed	0 / 38 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Rash generalised			
subjects affected / exposed	0 / 38 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Rash papular			
subjects affected / exposed	0 / 38 (0.00%)	0 / 35 (0.00%)	
occurrences (all)	0	0	
Urticaria			
subjects affected / exposed	0 / 38 (0.00%)	0 / 35 (0.00%)	
occurrences (all)	0	0	
Infections and infestations			
Acute sinusitis			
subjects affected / exposed	2 / 38 (5.26%)	0 / 35 (0.00%)	
occurrences (all)	2	0	
Bronchiolitis			
subjects affected / exposed	1 / 38 (2.63%)	0 / 35 (0.00%)	
occurrences (all)	1	0	
Bronchitis			
subjects affected / exposed	0 / 38 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Bronchitis viral			
subjects affected / exposed	0 / 38 (0.00%)	0 / 35 (0.00%)	
occurrences (all)	0	0	

Candida infection		
subjects affected / exposed	0 / 38 (0.00%)	1 / 35 (2.86%)
occurrences (all)	0	1
Cellulitis		
subjects affected / exposed	1 / 38 (2.63%)	0 / 35 (0.00%)
occurrences (all)	1	0
Conjunctivitis		
subjects affected / exposed	2 / 38 (5.26%)	0 / 35 (0.00%)
occurrences (all)	2	0
Enterovirus infection		
subjects affected / exposed	1 / 38 (2.63%)	0 / 35 (0.00%)
occurrences (all)	1	0
Gastroenteritis		
subjects affected / exposed	1 / 38 (2.63%)	0 / 35 (0.00%)
occurrences (all)	1	0
Gastroenteritis viral		
subjects affected / exposed	0 / 38 (0.00%)	0 / 35 (0.00%)
occurrences (all)	0	0
Hand-foot-and-mouth disease		
subjects affected / exposed	0 / 38 (0.00%)	0 / 35 (0.00%)
occurrences (all)	0	0
Hordeolum		
subjects affected / exposed	0 / 38 (0.00%)	1 / 35 (2.86%)
occurrences (all)	0	1
Impetigo		
subjects affected / exposed	0 / 38 (0.00%)	1 / 35 (2.86%)
occurrences (all)	0	1
Influenza		
subjects affected / exposed	0 / 38 (0.00%)	0 / 35 (0.00%)
occurrences (all)	0	0
Nasopharyngitis		
subjects affected / exposed	10 / 38 (26.32%)	9 / 35 (25.71%)
occurrences (all)	15	10
Oral herpes		
subjects affected / exposed	0 / 38 (0.00%)	0 / 35 (0.00%)
occurrences (all)	0	0

Otitis media		
subjects affected / exposed	0 / 38 (0.00%)	0 / 35 (0.00%)
occurrences (all)	0	0
Otitis media acute		
subjects affected / exposed	0 / 38 (0.00%)	0 / 35 (0.00%)
occurrences (all)	0	0
Paronychia		
subjects affected / exposed	0 / 38 (0.00%)	1 / 35 (2.86%)
occurrences (all)	0	1
Pharyngitis		
subjects affected / exposed	5 / 38 (13.16%)	3 / 35 (8.57%)
occurrences (all)	5	3
Pharyngotonsillitis		
subjects affected / exposed	0 / 38 (0.00%)	0 / 35 (0.00%)
occurrences (all)	0	0
Pneumonia		
subjects affected / exposed	0 / 38 (0.00%)	0 / 35 (0.00%)
occurrences (all)	0	0
Respiratory syncytial virus bronchitis		
subjects affected / exposed	1 / 38 (2.63%)	0 / 35 (0.00%)
occurrences (all)	1	0
Roseola		
subjects affected / exposed	1 / 38 (2.63%)	0 / 35 (0.00%)
occurrences (all)	1	0
Sinusitis		
subjects affected / exposed	1 / 38 (2.63%)	0 / 35 (0.00%)
occurrences (all)	2	0
Tonsillitis		
subjects affected / exposed	1 / 38 (2.63%)	0 / 35 (0.00%)
occurrences (all)	1	0
Upper respiratory tract infection		
subjects affected / exposed	6 / 38 (15.79%)	8 / 35 (22.86%)
occurrences (all)	6	9
Viral diarrhoea		
subjects affected / exposed	0 / 38 (0.00%)	0 / 35 (0.00%)
occurrences (all)	0	0

Viral infection			
subjects affected / exposed	0 / 38 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Viral rash			
subjects affected / exposed	0 / 38 (0.00%)	0 / 35 (0.00%)	
occurrences (all)	0	0	
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 38 (0.00%)	0 / 35 (0.00%)	
occurrences (all)	0	0	
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	14 / 38 (36.84%)	13 / 35 (37.14%)	
occurrences (all)	20	19	
Failure to thrive			
subjects affected / exposed	0 / 38 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported